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Background Progression of chronic kidney disease (CKD) remains an unsolved problem in 
clinical nephrology since approaches to reverse or repair chronic renal injury are not yet 
available. Independent of the underlying disease, loss of functional kidney parenchyma and 
tubulo-interstitial fibrogenesis are commonly observed when kidney injury progresses towards 
CKD. In this regard, epithelial-to-mesenchymal transition (EMT) in tubular epithelial cells 
(TECs) and consecutive G2/M arrest have been shown to determine maladaptive kidney repair in 
response to injury, ultimately associated with renal fibrogenesis and progression into CKD. 
Transforming growth factor β1 (TGF-β1) is considered as a key mediator of intrarenal EMT 
program and renal fibrosis. Neural cell adhesion molecule (NCAM) and fibroblast growth factor 
receptor (FGFR) signaling during EMT program have already been described and it has been 
noticed that both molecules are fundamental for EMT program in vitro. However, their cross-talk 
has been widely studied mainly in neural tissues and cancer cells, but there is a lacking of 
evidence for the contribution of their interplay to fibrogenesis, although several studies 
confirmed that both molecules can be separately involved in such process. Moreover, FGFR has 
been widely studied in many fields of research, including fibrosis, whereas NCAM contribution 
to renal fibrogenesis has been only suggested by two research groups (including our team). Thus, 
it encouraged us to investigate aforementioned molecules in human kidneys and to evaluate their 
significance in fibrotic response within the renal interstitial compartment. For the first time, here 
we present a functional significance of NCAM and FGFR co-operation in the induction of renal 
fibrosis, mediated by TGFβ-1. 
Material and methods In order to achieve goals of the study, we examined human kidney 
biopsy samples and performed cell culture experiments to clarify functional significance of 
NCAM/FGFR1 signaling in model of renal fibrosis. Immunostaining (immunohistochemistry 
and immunofluorescence) was performed to detect NCAM expressing cells in human kidneys in 
order to further characterize these cells and to label them for laser capture microdissection 
(LCM) which allows pure NCAM+ cells collecting for the subsequent qRT-PCR and gene 
expression analysis. Moreover, clinical relevance of both NCAM expressing renal interstitial 
cells and TGFβ-1 downstream effectors detection in human kidney biopsies were also examined. 
By using an established model of EMT program in human proximal tubular epithelial cells (HK-
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2 cells) in response to TGF-β1 (10ng/mL) exposure, NCAM/FGFR1 signaling responses were 
analyzed by light microscopy, immunolabeling, qRT-PCR and scratch assays. Modulation of 
NCAM/FGFR pathway was performed using PD173074 (100nM) - a small FGFR inhibitor. 
Results Significantly increased number of interstitial NCAM expressing cells has been detected 
in the adult kidneys with incipient interstitial renal fibrosis (incipient IRF, <25% of renal tissue 
affected with fibrosis), compared to advanced stages of renal fibrosis (p<0.001). Among 90 
biopsy samples of various glomerulonephritises and glomerulopathies, an increased NCAM 
positivity was found in 45.6% of cases and was found to be independent of the underlying 
disease. After applying qRT-PCR using mRNA obtained from laser captured NCAM+ positive 
cells, NCAM-140 isoform was significantly over-expressed in NCAM+ cells laser captured from 
incipient IRF (p=0.006), and in the same cells significant αSMA (p=0.014) and SLUG (p=0.004) 
mRNAs up-regulations were detected. These cells were highly heterogeneous, whereby sub-
populations shared some markers involved in fibrosis, such as HE4. However, interstitial NCAM 
expression did not have long term impact on disease outcome and could not be used as predictor 
for the impairment of kidney function. Moreover, NCAM interstitial positivity was frequently 
found in patients with lower proteinuria values. Since TGF-β is the main cytokine involved the 
fibrogenic response, here we underlined the influence of this signaling pathway (SMADs, 
SNAIL) on morphology of renal tubulointerstitial compartment suggesting its signaling cascade 
was closely related to tubular atrophy and interstitial fibrosis, resulting in higher creatinine and 
urea values, lower eGFR, CDK development and disease progression. Beside SMAD2 influence 
on morphology of renal tubulointerstitial compartment and patients’ outcome, SNAIL expression 
in podocytes was also associated with nephrotic range proteinuria. EMT program of TECs, 
induced by TGF-β, was morphologically noticed 48h after treatment and was clearly apparent 
after 72 hours, associated with loss of CDH1 (encoding E-Cadherin) and transcriptional 
induction of SNAI1 (encoding SNAIL), SNAI2 (encoding SLUG), TWIST1, MMP2, MMP9, 
CDH2 (encoding N-Cadherin), ITGA5 (encoding integrin-α5), ITGB1 (encoding integrin-β1), 
ACTA2 (encoding α-SMA) and S100A4 (encoding FSP1). During early EMT program, 
transcriptional induction of several NCAM isoforms (mostly NCAM-140 isofrom) along with 
FGFR1 was observed after 24 hours of TGF-β1 exposure, implicating a mechanistic link 
between NCAM/FGFR1 signaling and induction of EMT program. These observations were 
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further supported by inhibition of EMT program by PD173074 to specifically block FGFR1 
signaling responses. Beside significant suppression of mRNA and proteins of genes de-regulated 
during EMT, FGFR inhibitor succeeded to reduce cell migration previously enhanced by TGF-
β1. 
Conclusion NCAM expressing cells do not only increase during fibrogenesis but also switch 
the isoforms. Compared to NCAM expressing in normal human kidneys, these cells under 
fibrotic microenvironment highly express NCAM-140 isoform. NCAM expression in renal 
interstitial compartment is disease independent, representing a trait of early fibrogenesis in the 
human kidney. Furthermore, TGF-β signaling pathway activation, is found to be associated with 
chronic renal parenchymal damage (tubular atrophy and interstitial fibrosis), resulting in 
impaired renal excretory function and CDK development and progression. Modulation of 
NCAM/FGFR1 signaling by PD173074 blocks EMT program in cultured human proximal 
tubular epithelial cells, implicating novel insights into maladaptive repair and parenchymal 
damage during renal fibrosis. Unequivocally, FGFR inhibitor could be a promising anti-fibrotic 
strategy for kidney diseases and has to be further explored in details. Collectively, the most 
important finding in our study reflects a robust induction of NCAM expression in incipient renal 
fibrosis and an important role of NCAM/FGFR interplay in the initiation step of fibrogenic 
response that could be effectively suppressed by inhibition of their cross-talk applying FGFR 
inhibitor (PD173074). 
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Uvod Progresija hronične bubrežne insuficijencije predstavlja gotovo nerešiv problem kliničke 
nefrologije, imajući u vidu da su terapijski postupci koji bi doveli do zaustavljanja ili 
reverzibilnosti hroničnih oštećenja parenhima bubrega još uvek nedostupni. Sva hronična 
oboljenja bubrega dovode do progresivnog gubitka funkcionalnog parenhima i 
tubulointersticijske fibroze, indukujući pojavu hronične bubrežne insuficijencije. U tom pogledu, 
smatra se da je supstrat nemogućnosti regeneracije oštećenog parenhima bubrega zapravo 
fenomen epitelno-mezenhimne transformacije (EMT) sa sledstvenim G2/M zastojem u fazi 
ćelijskog ciklusa koji dovodi do nastanka fibroze i progresije hronične bubrežne insuficijencije. 
Smatra se da je glavni medijator EMT programa i fibroze u bubregu transformišući faktor rasta 
β1 (TGF-β1). Opisano je da se tokom EMT programa indukuje ekspresija neuralnog ćelijskog 
adhezionog molekula (NCAM) i receptora za fibroblastni faktor rasta (FGFR), koji imaju važnu 
ulogu u in vitro EMT. Međutim, značaj međusobnih interakcija NCAM i FGFR molekula do 
sada je prevashodno ispitivan u neuralnom tkivu i različitim malignim oboljenjima, dok nema 
podataka o značaju ovih interakcija tokom procesa fibroze, iako je nekoliko studija potvrdilo da 
individualno NCAM i FGFR molekul mogu biti uključeni u ovaj proces. Štaviše, FGFR je 
izučavan u mnogim patološkim procesima, uključujući i fibrozu, dok je povezanost NCAM 
molekula sa procesom fibroze u bubregu sugerisana od strane samo dva istraživačka tima 
(uključujući i naš). Stoga smo poželeli da ispitamo prethodno pomenute molekule u bubrezima 
čoveka i da procenimo njihov značaj u procesu fibrogeneze. Po prvi put, u ovoj studiji 
prikazujemo funkcionalni značaj NCAM/FGFR interakcija u indukciji fibroze bubrega, 
posredovanoj TGF-β1. 
Materijal i metode U svrhu ispitivanja zadatih ciljeva studije, korišćeni su uzorci humanih 
biopsija bubrega kao i eksperimenti na ćelijskim kulturama kako bi se razjasnio funkcionalni 
značaj NCAM/FGFR1 signalnog puta u modelu fibroze bubrega. Primenjene su 
imunohistohemisjke i imunofluorescentne tehnike detektovanja NCAM eksprimirajućih ćelija sa 
ciljem njihove bolje krakterizacije i vizuelizacije, kao i radi sprovođenja laserske mikrodiskcije 
(LCM) koja omogućava sakupljenje izolovanih NCAM+ ćelija za dalja ispitivanja genske 
ekspresije metodom real-time RT-PCR (qRT-PCR). Takođe, ispitan je klinički značaj prisustva 
NCAM+ ćelija u intersticijumu bubrega kao i značaj detekcije nishodnih efektora TGF-β1 
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signalnog puta u biopsijskim uzorcima. Korišćenjem modela EMT programa indukovanog uz 
pomoć TGF-β1 (10ng/mL) na humanoj ćelijskoj liniji proksimalnih tubulskih epitelnih ćelija 
bubrega (HK-2 ćelijka linija), analiziran je značaj NCAM/FGFR1 signalnog puta uz pomoć 
metoda svetlosne mikroskopije, imunobojenja, qRT-PCR i migracionog eseja (scratch assays). 
Modulacija NCAM/FGFR1 interakcija sprovedena je korišćenjem PD173074 (100nM) - FGFR 
inhibitora. 
Rezultati Značajan porast broja NCAM eksprimirajućih ćelija u intersticijumu bubrega 
detektovan je u početnoj fazi interstcijske fibroze (<25% tkiva zahvaćeno fibrozom), poređenjem 
sa uznapredovalijim stadijuma fibroze (p<0.001). Analizom 90 biopsijskih uzoraka različitih 
glomerulonefritisa i glomerulopatija, povećan broj NCAM ćelija uočen je kod 45.6% ispitanika i 
nalaz je bio nezavistan od patohistološke dijagnoze. Primenom qRT-PCR metode, korišćenjem 
mRNA dobijene iz NCAM+ ćelija prikupljenih laserskom mikrodisekcijom, uočeno je da 
NCAM+ ćelije u početnoj fazi fibroze imaju povećanu ekspresiju NCAM-140 izoforme 
(p=0.006), kao i da pojačano eksprimiraju αSMA (p=0.014) i SLUG (p=0.004) gene. NCAM+ 
ćelije pokazivale se međusobno značajnu heterogenost, pri čemu su pojedine populacije ovih 
ćelija eksprimirale neke od molekula značajnuh u procesu fibrogeneze, kao što je HE4. Međutim, 
prisustvo intersticijske ekspresije NCAM molekula nije imalo dugotrajan uticaj na tok i ishod 
bolesti bubrega, tako da ovaj parametar ne može biti korišćen kao prediktor pogoršanja 
ekskretorne funkcije bubrega. Štaviše, NCAM intersticijska imunoreaktivnost češće je 
detektovana kod pacijanata sa nižim vrednostima proteinurije. S obzirom na to da je TGF-β 
glavni citokin uključen u proces fibrogeneze, imunomorfološkom detekcijom efektora ovog 
signalnog puta (SMAD proteini, SNAIL) uočili smo da je njihovo prisustvo značajno povezno sa 
morfološkim karakteristikama hroničnog oštećenja bubrežnog parenhima (tubulska atrofija i 
intersticijska fibroza), kao i da klinički korelira sa značajno višim vrednostima serumskog 
kreatinina i uree, ali i sa sniženim vrednostima jačine glomerulske fitracije (eGFR), te sa 
razvojem hronične bubrežne insuficijencije i njene progresije u više CKD stadijume. SNAIL je, 
kao i SMAD2, bio povezan hroničnim lezijama u tubulointerstcijumu i ishodom bolesti bubrega, 
ali je pored ovih obrazaca ispoljavanja uočena i značana detekcija ovog molekula u podocitima 
pacijenata sa nefrotskim vrednostima proteinurije. TGF-β1 indukovan EMT program u ćelijskoj 
liniji, morfološki je bio primetan 48h nakon stimulacije TGF-β1, ali su se jasni morfološki znaci 
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EMT mogli uočiti tek 72h od započinjanja eksperimenta i bili su udruženi sa gubitkom ekspresije 
CDH1 (enkodira E-Cadherin) i sa transkripcionom indukcijom SNAI1 (enkodira SNAIL), 
SNAI2 (enkodira SLUG), TWIST1, MMP2, MMP9, CDH2 (enkodira N-Cadherin), ITGA5 
(enkodira integrin-α5), ITGB1 (enkodira integrin-β1), ACTA2 (enkodira α-SMA) and S100A4 
(enkodira FSP1). U toku rane, inicijalne faze EMT, već 24h nakon stimulacije TGF-β1 
detektovana je jasna indukcija ekspresije sve tri NCAM izoforme (najviše NCAM-140 izoforme) 
kao i FGFR1, sugerišući mehanističku povezanost između NCAM/FGFR1 signalnog puta i 
indukcije EMT programa. Ove opservacije su dalje potkrepljene činjenicom da je EMT uspešno 
suprimiran kada se blokirao FGFR signalni put uz pomoć PD173074. Pored značajne inhibicije 
ekspresije mRNA i proteina značajnih u procesu EMT, FGFR inhibitor je takođe uspešno 
usporio migraciju ćelija koja je prethodno bila stimulisana TGF-β1 uticajem. 
Zaključak U toku procesa fibrogeneze u bubregu, NCAM eksprimirajuće ćelije pored toga što 
postaju brojnije u ranoj fazi ovog procesa, one takođe menjaju značajno i izoformu molekula. U 
poređenju sa NCAM+ ćelijama u normalnom intesticijumu, ćelije u fibrozi značajno više 
eksprimiraju NCAM-140 izoformu. Ekspresija NCAM molekula nezavisna je od bolesti koja u 
osnovi zahvata bubreg, već prestavlja karaktersitiku ranih faza fibroze bubrega kod čoveka. 
Takođe, aktivacija TGF-β signalnog puta udružena je sa hroničnim oštećenjima parenhima 
bubrega (atrofija tubula i fibroza intersticijuma), dovodeći do poremećaja ekskretorne funkcije 
bubrega i razvoja i progresije hronične bubrežne insuficijencije. Modulacija NCAM/FGFR1 
signalnog puta korišćenjem PD173074 blokira EMT u kulturi epitelnih ćelija proksimalnih 
tubula bubrega, ukazujući na nove mehanizme uključene u proces oštećenja parenhima bubrega i 
reparacije. Nedvosmisleno, FGFR inhibitor bi mogao biti obećavajući anti-fibrotski agens u 
bubregu i trebalo bi ga dalje detaljnije ispitivati. Sveobuhvatno, najvažniji nalaz u našoj studiji 
ukazuje na izraženu indukciju NCAM ekspresije u početnim fazama intersticijske fibroze i 
značaj NCAM/FGFR interakcija u incijaciji procesa fibroze koja bi mogla biti uspešno 
suprimirana inhibicjom ovog signalnog puta primenom FGFR inhibitora (PD173074). 
Ključne reči NCAM, FGFR, PD173074, fibroza 
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Proper kidney function is important for the regulation of many physiological processes and 
consequently plays an important role in homeostasis. Excretory and homeostatic kidney 
functions include elimination of metabolic products through the urine, regulation of the fluid 
volume, as well as acid-base balance and electrolyte concentration. Additionally, kidney is also 
recognized as endocrine organ which produce and secrete hormones such as erythropoietin 
(EPO), renin, calcitriol and klotho. Through these endocrine functions kidney regulates 
erythropoiesis, blood pressure and mineralization of the bones. All these kidney functions require 
preserved kidney morphology and integrity of molecular pathways. Thus, any impairment on 
these levels could also induce disturbance in essential functions of kidney, either transient or 
permanent, with ability or disability to recover it (1, 2). 
The majority of kidney diseases have chronic course. Either primarily glomerular or 
tubulointerstital diseases, during the chronic course, result in the excessive accumulation of 
fibrous tissue, especially within the tubulointerstital compartment. Thus, renal interstitial fibrosis 
could be the common feature of all kidney diseases, leading to chronic renal failure (3). 
Fibrosis is considered as an injury-induced tissue response composed of inflammation, cytokines 
release, fibroblast activation/proliferation and deposition of matrix scaffold. It resemble normal 
tissue repair in many aspects and differ from it only in terminal phase. While normal tissue repair 
terminates with resolution of inflammation, matrix scaffold degradation and myofibroblasts 
apopotosis, fibrosis represent dysregulated repair seems as permanently active biosynthetic 
process with excessive deposition of extracellular matrix (ECM) components, accompanied by 
accumulation of fibroblasts and inflammatory cells, rarefactions of peritubular microvasculature 
and tubular damages (tubular atrophy and loss of tubular epithelial cells) (4-7). Only severe 
fibrosis resulting in scaring formation could be macroscopically visible. Like many organs, 
kidneys with severe and widespread fibrosis are stiff due to excessive ECM deposition, pale due 
to rarefaction of peritubular microvasculature, and have bumpy surface due to fibroblast 
contraction. Usually, slight and less severe fibrosis is visible under the microscope and is 
characterized by widening of interstitial space filled with ECM components (qualitatively 
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different from normal), fibroblasts (very rare in normal kidney tissue) and other cells (such as 
inflammatory cells) (8). 
Persistent effort to modulate this natural course of kidney diseases has led the scientists to better 
understanding of molecular mechanisms driving renal fibrosis. Preclinical studies found many 
effective strategies to mellow-down interstitial fibrosis in the animal kidneys, however, only a 
few of them are applicable in humans (9-13). Further investigations in the field of molecular 
background of renal interstitial fibrosis and signaling pathways driving initiation, maintenance 
and progression of such process could contribute to better understanding of the complex network 
involved in renal fibrosis and permit development of new potential strategies to treat renal 
fibrosis in humans. Moreover, a special focus should be on the activation of genes highly 
expressed during embryonic kidney development and its potential reactivation during wound 
















1.1.Pathophysiology and morphology of renal fibrosis 
Extracellular matrix 
In addition to quantitative changes in the matrix, fibrosis could be also followed by the 
qualitative modifications of ECM (9). The main feature is the accumulation of collagens fibers, 
types I and III, and several fibronectin splice variants that modulate fibrogenesis. Moreover, 
fragments of collagen IV could be also detected within the fibrotic interstitium, although this 
collagen type normally constitutes basement membranes of the tubular epithelium and vascular 
endothelium. Fibrillar collagen assemble depends on numerous interaction partners in vivo, such 
as fibronectin, collagen type V, integrins (fibronectin and collagen binding), fibrillins (i.e. latent 
TGF-β binding proteins - LTBP), and secreted protein acidic and rich in cysteine (SPARC). 
Fibronectin co-localizes with pro-collagen secretion on fibroblasts. Collagen type V assists in the 
assembly of collagen type I. α5β1 integrin cooperates in cell adhesion, proliferation and 
differentiation and plays a role in extracellular matrix assembly (5, 14, 15). LTBP facilitate the 
secretion of pro-TGF-β and support its release and activation. SPARC serves as protective, 
antiproliferative actor, since it stimulates matrix metalloproteinases (MMPs) and plasminogen 
activator inhibitor-1 (PAI-1). All these mechanisms modulate collagen matrix both in normal and 
altered tissues (6). 
At the beginning, fibrosis is a focal feature with tendency to be widespread in the persistence of 
profibrotic microenvironment. Expansion of ECM in renal fibrosis, which induces the widening 
of interstitial space, appears due to excessive production by matrix-producing cells and/or 
decreased degradation due to suppressed activities of tissue proteases (5, 9, 16, 17).  
Matrix-producing cells 
The major role in renal fibrosis belongs to activated fibroblasts, also known as myofibroblasts (4, 
18). However, the origin of abundantly observed myofibroblasts within fibrotic areas is still 
debatable, especially considering that, in contrast to other human organs, normal renal tissue 
contains scarce fibroblasts (1). Thus, it is difficult to assign a collagen secretion to any particular 
cell type found within the fibrotic area. Instead, applying different strategies it is possible only to 
insinuate a collagen secretory function. Usually, in situ hybridization of mRNA encoding 
collagen chains, collagen poromoter activity and collagen containing cells are used as surrogate 
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markers of secretory activity. Otherwise, endoplasmic expression of HSP47, collagen type I 
chaperone could be even more related to secretion (19).  Some of the supposed ECM-producing 
cells are shown on the Figure 1.    
 
Figure 1. Origin of matrix-producing cells. 
Fibroblasts 
Unlike other organs, normal human kidneys are devoid of numerous fibroblasts. An increased 
number of fibroblasts appear during renal fibrosis, as a common event of all chronic kidney 
diseases. However, these fibroblasts display huge phenotypic heterogeneity, probably relay on 
the different origin. It has been suspected that the pool of fibrogenic fibroblasts could derive 
from resident fibroblasts, tubular epithelial and vascular endothelial cells (during epithelial to 
mesenchymal transformation (EMT) and endothelial to mesenchymal transformation (EndMT) 
processes initiated by tissue injury), bone marrow-derived fibrocytes, and from pericytes.  
Unfortunately, the conclusions of the previous studies manly derived from the cell culture 
experiments and from the manipulations on animal models. Thus, it is not easy to realize what 
really happens in the humans. Otherwise, it is not yet clear whether the aforementioned pool of 
fibrogenic cells should be considered as true fibroblasts or only as a separate phenotype of 
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collagen-producing cells. Moreover, it is less likely that all tissue fibroblasts are potentially 
fibrogenic (16, 20, 21). 
Overall, it clear that fibroblast population is highly heterogeneous. According to the molecules 
expressed by these cells, their functions can be discovered. Thus, it has been accepted that 
fibroblasts must be activated to produce ECM components and during such activation they 
acquire new phenotype and convert to myofibroblasts (21). During that process, the main 
characteristic is acquisition of α-smooth muscle actin (α-SMA) that is normally expressed by 
smooth muscle cells, such as vascular. Additionally, activated fibroblasts acquire various 
phonotypical characteristics making them different from normal kidney fibroblast. Some of the 
fibroblasts traits are expression of CD90, CD73, PDGF receptors and S100A4 (FSP-1) (22). 
The main differences among resident fibroblast in normal renal tissue and those in renal fibrosis 
are related to their proliferative capacity and ECM synthesis capacity (23). One of the molecules 
involved in fibroblast activation and proliferation is fibroblast growth factor receptor 1 (FGFR1) 
that can be activated by FGF and many different ligands including neural cell adhesion molecule 
(NCAM) (24, 25). Activation of FGFR1 by NCAM interaction additionally promotes FGFR1 
recycling, resulting in sustained FGFR1 signaling that is important for fibroblast migration (26, 
27). It has been also shown that α5β1 integrin expressed by fibroblasts promotes acquisition of a 
myofibroblastic phenotype (with a typical α-SMA expression pattern), which constitute the 
dominant interstitial cells in a pro-fibrotic microenvironment (4, 5, 16). Another up-regulated 





a protein which suppresses the activity of multiple proteases, 
including serine proteinase and matrix metalloproteinases, and inhibits their capacity to degrade 
type I collagen (29). 
Bone-marrow derived fibrocytes 
Possible mechanism consider the influx of bone-marrow derived fibrocytes (collagen 
I/CD34/CD45 expressing cells) into the area of local injury, able to differentiate into the matrix 
producing myofibroblasts in response to local TGF-β stimuli (30, 31). However, it has been 
shown that influx of these fibrocytes in the fibrotic kidney is scarce and these fibrocytes did not 




Tubular epithelial cells are also considered as contributors of renal interstitial fibrosis, through 
synthesis of ECM components. This phenomenon is well studied in the in vitro cell culture 
experiments, through the induction of EMT. The well known EMT inducers are hypoxia, TGF-β 
and EGF which stimulate broad spectrum of epithelial cells changes until they complete 
transition and become fibroblasts (33). Through such transformation, many intermediate cell 
phenotypes appear means they start to lose their epithelial and acquire mesenchymal traits (34). 
Low rate turn-over of tubular epithelial cells is a limiting factor in tubular regeneration after 
injury (35). Tubular injury can be acute, with ability to recover damages if the cause of damage 
is removable. Unfortunately, if the cause of injury persists, tubular epithelial cells are chronically 
exposed to bad stimuli and should undergo adaptive response. Step by step, these reactions lead 
to terminal dysfunction of tubular epithelial cells, morphologically characterized by tubular 
atrophy (36).  
Tubular atrophy could appear in the case of primarily tubulointerstitial injuries, as well as a 
secondary phenomenon of various forms of glomerular diseases with subsequent affection of 
tubulointerstitial compartment. Once become atrophic, regeneration would not be possible. Since 
the main consequence of chronically affected tubulointerstitial compartment would be 
deterioration in kidney function, leading to terminal insufficiency, there are an increasing efforts 
to prevent this chronic injury (37). 
Pericytes end endothelial cells 
Several studies identified pericytes and vascular endothelial cells as the major sources of 
interstitial myofibroblasts (32, 38-41). Thus, the scientific focus switched from tubular to 
vascular injury in many research groups. 
Mesenchymal stem cells 
Considering and ability of mesenchymal stem cells to differentiate in several cell lineage, 
including fibroblasts, they are also recognized as one of the putative origin of matrix producing 





Endogenous potential to remove excessively produced ECM depends on protease activity, 
preferably MMPs and members of plasmin dependant pathway. These families of proteases are 
able to fragment components of ECM further suitable for removal. Unfortunately, under certain 
circumstances they are also able to release profibrotic growth factors triggering undesirable 
events. MMP family includes 25 members of zinc-dependant endopeptidases. They are divided 
in several categories: collagenases (MMP1, MMP8, MMP13), gelatinases (MMP2, MMP9), 
stromelysins (MMP3, MMP10, MMP11), membrane-type MMPs (MMP14, MMP15, MMP16, 
MMP17, MMP24, MMP25), matrilysin (MMP7, MMP26), enamelysin (MMP20), 
metalloelastase (MMP12), other types (MMP19, MMP21, MMP23A, MMP23B, MMP27, 
MMP28). Tissue inhibitors of metalloproteinases (TIMPs) control their activities and they are 
named TIMP1-4. Among MMPs, gelatinases (MMP2 and MMP9) are the most frequently 
studied in the kidney. It has been found that both MMP2 and MMP9 are able to degrade collagen 
type IV, as a main component of basement membrane (both tubular end endothelilal), and has 
been suspected that they could be able to affect also collagens type I and III, however without 
evidence of antifibrotic potential in interstitial compartment. Moreover, the effect of these MMPs 
could be “stage specific”, since their inhibition in advanced disease stage could accelerate 
fibrosis, while inhibition before the onset of fibrosis could be protective. MMP2 overexpression 
in tubular epithelium could be sufficient to induce fibrosis itself. Overall, it seems that MMP2 
and MMP9 profibrotic potential outweigh their antifibrotic activities in the kidney. TGF-β 
mediated activation of MMP2 and MMP14 (a membrane-bound activator of secreted MMP2 and 
MMP9 in fibroblasts) is associated with basement membrane destruction, as one of the initial 
events during EMT. MMP14 expression is induced by SNAIL transcription factor that is one of 
the key down-stream mediators of TGF-β signaling pathway and EMT process. Plasmin-
dependant pathway is also involved in the extracellular matrix remodeling. Whole network is 
really complex and the effects tissue proteases depend on the biochemical microenvironment. 
Shortly, tissue-type plasminogen activator (tPA) produces active plasmin by the proteolytic 
plasminogen cleavage. Active plasmin is able to destroy some ECM components such as laminin 
and fibronectin, as well as to change cell behavior through activation of MMPs. Thus, interplay 
between MMPs and plasmin dependant pathway could serve as a profibrotic mechanism 




Infiltration with inflammatory cells is usually seen in the area of renal interstitial fibrosis, at least 
in some extent. This cell population is composed of lymphocytes, macrophages, dendritic and 
mast cells. Some subsets of these cells could be profibrotic, while the others could even serve as 
antifibrotic strategies. Lymphocytes are highly heterogeneous and represent the first cell 
population that infiltrate the interstitium and come even before macrophages. Among them, 
CD3+ T lymphocytes are well established contributors to renal fibrosis, while on the other hand 
the involvement of B lymphocytes is not clear. Interstitial macrophages have very important 
regulatory role in interstitial fibrosis. Depending on the way of their activation, classically or 
alternatively, two main macrophages populations are defined: M1 and M2. M1 macrophages 
accelerate renal interstitial fibrosis, while M2 macrophages are anti-inflammatory and provide 
tissue repair. Dendritic cells are antigen presenting cells in tubulointerstitial injury. However, 
they are not widely studied in the context of renal fibrosis. Although mast cells are considered as 
contributors to fibrosis in many organs, in the kidney they paradoxally suppresses fibrosis. 
Currently, some purposed therapeutic strategies to modulate fibrogenesis are based on the 
modulation of inflammatory cell response. Thus, blocking of TGF-β, TNF-α and IL-1 signaling 
are already investigated and effects are promising (8, 45). 
Microvasculature 
At the beginning, transient ischemia, trough activation of pro-apoptotic stimuli, causes the 
damage of peritubular microvasculature that becomes completely remodeled during progression 
of renal interstitial fibrosis. Peritubular microvasculature in advanced stages is scarce, either due 
to imbalance between pro- and antiangiogenic stimuli or due to loss of endothelial cells 
underwent EndMT. Rarefaction of microvasculature in kidney emphasize hypoxic conditions, 
serving as a great medium for further matrix synthesis by fibroblasts (known as a cells “enjoy” in 






1.2.Mechanisms and molecular background of renal interstitial fibrosis 
Fibrosis in parenchymal organs can be presented by three-step model.  
1) Primary injury of epithelial cells stimulate them to release cytokines which afterwards 
attract inflammatory cells to the site of the primary damages 
2) Infiltrating inflammatory cells also produce cytokines which in turns affect epithelial 
parenchymal cells and also activate fibroblasts to produce ECM components and 
stimulate their proliferation 
3) Fibrogenesis includes maintenance and progression of fibrotic tissue response and 
depends on the presence of self-stimulating mechanisms persisting even after primary 
cause of injury and inflammation disappears    
Myofibroblasts are the main highly specialized cells responsible for ECM production, both in 
normal tissue repair and during fibrogenesis, and represented activated fibroblasts with typical 
expression of α-SMA. The major initial fibroblasts activator is TGF-β, released locally from the 
injured epithelial cells and inflammatory cells (20, 48). Once activated, myofibroblasts produce 
TGF-β themselves providing self-sustaining mechanisms characteristic of fibrosis (49, 50). 
Nevertheless, TGF-β is a powerful stimulus for ECM synthesis especially collagen type I and 
fibronectin, as well as a potent inducers of EMT in vitro. Collagen and fibronectin together act as 
EMT facilitators stimulating cell migration (51). Widened interstitial space due to expansion of 
ECM leads to limited oxygen supply to parenchymal cells additionally causing epithelial injury 
and providing deeper and deeper tissue hypoxia which in turns further stimulates fibrogenesis. 
Epithelial to mesenchymal transition (EMT) and fibrosis  
EMT is a mechanisms involved in many events during embryogenesis such as formation of 
mesoderm and neural crest, aimed to create cells with ability to move and produce matrix (50). 
Tubular EMT is a highly regulated process consisting of four steps: (1) loss of epithelial cell 
adhesion, (2) de novo expression of mesenchymal markers such as α-SMA and reorganization of 
actin cytoskeleton, (3) disruption of TBM, and (4) enhancement of cell migration and invasion. 
Thus, the main features during EMT are epithelial cell detachment from the neighboring cells 
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and basement membrane, as well as movement into interstitium where they may start to produce 
matrix (33). 
Following the transformation, epithelial cells pass through many transient phenotypes 
progressively losing their epithelial and acquiring mesenchymal characteristics. Thus, E-cadherin 
down-regulation is one of the earliest molecular hallmarks of EMT, which afterwards leads to 
loss of cell-cell adhesion and detachment from the neighboring epithelial cells. At this step, 
activity of proteases (such as MMP-2, MMP-9 and MMP-14) is up-regulated aimed to digest 
basement membranes and allow cell migration into interstitial space. Transcription factors 
underlying EMT events (such as β-catenin, SMADs and SNAIL family) are also up-regulated 
and/or translocated into nuclei. Rho GTPase (Ras homologues guanosine triphosphatase) – 
mediated cytosceletal reorganization favor changes in cell shape and promote cell motility. 
Additionally, rearrangement in cytosceleton could be supported by activation of integrin-linked 
kinase (ILK) and β-catenin pathway. Upon EMT, cells start to express mesenchymal markers 
such as vimentin and S100A4 (FSP-1), and also markers of myofibroblasts such as α-SMA (52).  
Normal epithelial cells make a contact with basement membrane which separate them from 
interstitial compartment and prevent contact with ECM components. When basement membrane 
is degraded, the contact of epithelial cells with interstitial microenvironment (such as collagens, 
fibronectin and perhaps TGF-β) allows them to further destabilize epithelial phenotype and 
enhance EMT. Three main molecular pathways are crucial in the induction of EMT process, 
including Wnt/β-catenin, extracellular matrix/ILK and TGF-β/SMAD signaling (Figure 2). The 
central common downstream target of the aforementioned pathways is SNAIL family of 
transcription factors. Transcription activity of SNAIL results in down-regulation of epithelial and 
up-regulation of mesenchymal molecules (10, 52-54). 
In normal epithelial cells, glycogen synthase kinase-3β (GSK-3β) is constitutively active and 
phosphorylates SNAIL thereby targeting it for cytoplasmic degradation and preventing its 
nuclear translocation, thus acting as negative regulator of SNAIL activity. Both ILK and Akt 
kinase are able to phosphorylate GSK-3β and inhibit its activity which afterwards leads to 
increase SNAIL activity that enhances EMT. TGF-β/SMADs directly stimulate SNAIL 
transcription and also transcription of ILKs that in turns cooperate in additional promotion of 
SNAIL activity (55). TGF-β stimulates pathways involving Rho GTPase that is responsible for 
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reorganization of cytoskeleton in order to favor cell shape changes and improve cell motility 
(56).  
 
Figure 2. Signaling pathways involved in EMT and fibrosis in kidney.  
Transforming growth factor-β (TGF-β) / SMAD pathway 
TGF-β, secreted by inflammatory and injured epithelial cells, binds to its receptors type I and 
type II. Signaling pathway is initiated by TGF-β binding to type II receptor which recruits and 
phosphorylates type I receptor. After that, type I receptor further phosphorylates cytoplasmic 
SMAD2 and SMAD3 proteins which then make a complex with SMAD4 protein. SMAD 
complex then translocate into nucleus and bind to specific DNA sequence motifs, acting as 
transcription activator of many genes including SNAIL. At this point, SMADs complex also 
induce transcription of ILK which suppresses E-cadherin and up-regulates MMP-2 and 
fibronectin. SMADs are involved in the activation of Rho/Rho kinase (ROK) pathway and in the 
transcription of α-SMA (10, 54, 57). TGF-β ligands and receptors are summarized in Table 1. 
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Activin A ACVR2A ACVR1B (ALK4) SMAD2/3 SMAD4 Follistatin 
GDF1 ACVR2A ACVR1B (ALK4) SMAD2/3 SMAD4  
GDF11 ACVR2B ACVR1B (ALK4), TGFβRI (ALK5) SMAD2/3 SMAD4  
BMPs BMPR2 BMPR1A (ALK3), BMPR1B (ALK6) SMAD1/5/8 SMAD4 Noggin, 
Chordin, DAN 
Nodal ACVR2B ACVR1B (ALK4), ACVR1C (ALK7) SMAD2/3 SMAD4 Lefty 
TGF- βs TGFβRII TGFβRI (ALK5) SMAD2/3 SMAD4 LTBP1, THBS1, 
Decorin 
There are three distinct SMADs classes based on their roles in TGF-β family signaling 
transduction: R-SMADs (receptor-regulated SMADs), Co-SMAD (common SMAD) and I-
SMADs (inhibitory SMADs). They are summarized in the Table 2. 
Table 2. SMAD proteins divided in three classes.  
 
R-SMADs become phophorylated after TGF-β binding to its type I and type II receptors. 
Phosphorylated R-SMADS then bind to Co-SMAD making a complex that translocate into 
nucleus and regulate gene transcription. I-SMADs attenuate TGF-β signaling by blocking the 
interaction with TGF-β receptors and/or compete with Co-SMAD for the generation of R-
SMAD/Co-SMAD complex. TGF-β/SMAD signaling can be modulated by Wnt/GSK-β, Rho 














In TGF-β-mediated renal fibrosis the major down-stream R-SMADs are SMAD2 and SMAD3, 
while SMAD7 controls inflammation (57). Regulation of the cellular SMADs concentration is 
mainly regulated by ubiquitin-mediated degradation through Smufr1 and Smurf2. 
Polyubiquitinatination of SMAD2 is reported to be mediated by SMURF2, NEDD4L, or WWP1, 
while SMAD3 is polyubiquitinated by CHIP. Phosphorylated SMAD2/3 can be 
polyubiquitinated by ARKADIA after the target gene transcription is initiated (59).  
Extracellular matrix / ILK pathway 
Integrin-linked kinase (ILK) is cytoplasmic serin-threonine kinase that interacts with cytoplasmic 
domain of β-integrin. Thus, ILK is transducer of integrin-mediated signals from extracellular 
matrix. Moreover, ILK can be activated by growth factors-mediated and cytokine-mediated 
ligands. As mentioned above, TGF-β/SMAD can also induce ILK transcription and participate in 
this signaling pathway. Activated ILK phosphorylate GSK-3β and inhibit its activity, whereby 
influence up-regulation of SNAIL and enhance β-catenin pathway (52).   
Wnt / β-catenin pathway 
Wnt cell surface receptors can be stimulated with extracellular Wnt glycoproteins leading to 
activation of this pathway which results in inhibition of GSK-3β and cytoplasmic accumulation 
of β-catenin. Finally, β-catenin translocates into nuclei acting as transcription activator of 
SNAIL, MMPs, vimentin and fibronectin. Without Wnt-mediated signals, β-catenin makes 
junction complex with E-cadherin. Free non-bound cytoplasmic β-catenin rapidly become 
phosphorylated by GSK-3β and marked for proteasomal degradation. Indirectly, Wnt pathway 
can be stimulated by ILK activity which inhibits GSK-3β and leads to β-catenin accumulation 
(53).   
Rho GTPases 
Rho GTPase is family that regulates balance between inactive (GDP) and active (GTP) form, 
influencing assembly or disassembly of actin-based structures. Rho activates ROK which in 
turns stimulate assembly of actin-myosin filaments by increasing the level of phosphomyosin. 
The result of the activation of Rho GTPase axis is enhanced cellular contractility underling 
movement – one of the crucial events during EMT (56).   
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1.3.Clinical relevance of signaling pathways and implication of anti-fibrotic 
therapies  
TGF-β/SMADs in renal diseases 
Precursor of TGF-β 
Three major TGF-β isoforms (β1, β2, β3) are widely expressed and secreted in latent forms, 
forming a complex with the relevant LTBPs (latent TGF-β binding proteins) (54). Proteolytic 
cleavage enable forming active TGF-β forms, and TGF-β1 is considered as a major mediator in 
fibrosis. However, a latent TGF-β is not only a simple precursor of active form, but also acts as a 
protective agent in renal fibrosis (60-61). The precise mechanism is not completely clear, 
however, it might be that protective effects of the latent TGF- β relay on the elevation of 
endogenous SMAD7. 
TGF-β receptors 
TGF- β signaling depends on the phosphorylation of TGF- β receptors, types I and II (TβRI, 
TβRII), which further phosphorylate SMADs. In the experimental models of fibrosis, in vivo and 
in vitro, TβRI was highly over-expressed, thus specific inhibitor of this receptor (SD-208) was 
able to diminish fibrogenic response (62). Nevertheless, the involvement of TβRII in fibrosis is 
highly organ and cell-dependant. Thus, disruption of this receptor in tubular epithelial cells and 
in fibroblasts results in the inhibition of TGF-β/SMAD3 signaling and protects from fibrosis. 
However, such approach is not able to block ERK/p38 MAP kinase pathway. On the other hand, 
blocking of TβRII in collecting ducts is rather adverse, leading to enhanced renal fibrosis 
perhaps due to paracrine TGF-β signaling between epithelial and interstitial cells. Both TβRI and 
TβRII interact with Hsp90 (heat-shock protein 90kDa) resulting in prevention of TGF-β 
receptors’ degradation. Thus, inhibition of Hsp90 reduces TGF-β signaling and related 
fibrogenic response, by elevation of SMAD7/Smurf2 dependant ubiqutination of TβRI and 





Roles of R-SMADs 
Both SMAD2 and SMAD3 are major TGF-β down-stream mediators in renal fibrosis. Several in 
vivo models of Smad3-knockout mice showed significant fibrotic response, and suggested that 
SMAD3 can be a critical mediator of TGF-β induced renal fibrosis. Furthermore, Hsp-72 
suppressed TGF-β induced phosphorylation of SMAD3 and prevented its nuclear translocation 
leading to inhibition of tubulointerstitial fibrosis in rat model. Moreover, SMAD3 has been also 
associated with many fibrogenic genes, such as several collagen types, as well as TIMMP-1. 
Specific SMAD3 inhibitor could block TGF-β induced EMT and attenuate diabetic 
glomerulosclerosis. However, the role of SMAD2 in renal fibrosis is still controversial, since 
several studies demonstrated protective role of SMAD2 in fibrogenic response by regulating 
SMAD3 signaling. TGF-β mediated gene expressions could decrease through BMP-7 activities 
which block the activation of SMAD-dependant and SMAD-independent pathways (such as 
ERK and MAPK through SMAD1 and SMAD5 activations). It has been also reported that 
SMAD2 and SMAD3 can be activated independently of TGF-β signaling, such as direct and 
angiotensin dependant MAPK-SMAD crosstalk. Moreover, SMAD3 plays an adverse role even 
in acute kidney injury enhancing TGF-β mediated tubular cell apoptosis by activation of pro-
apoptotic genes, such as Bcl-2-associated death promoter (BAD) (58).   
Roles of Co-SMAD 
SMAD4 is not only important for nuclear translocations of SMAD3, but also plays an important 
role in the initiation of SMAD3 targeted genes transcription. Blocking of SMAD4 up-regulation 
results in the reduced accumulation of ECM (58). 
Roles of I-SMADs 
In animal models, decreased SMAD7 expression potentiates TGF-β signaling paving the way to 
progressive renal fibrosis, and also increases renal inflammation by activation NF-κB response. 
Nevertheless, SMAD7 over-expression reduces renal inflammation by suppressing the release of 





Implications for therapies 
Suppression of TGF-β1 and its receptors, blockade of SMAD signaling and suppression of its 
downstream effectors are three global approaches for further perspectives in the treatment of 
renal fibrosis. Some of the purposed agents are: neutralizing TGF-β antibodies, TβR inhibitors, 
Hsp90 inhibitors, SMAD3 inhibitors and SMAD7 agonist. Gene therapy is also considered, but 
far away from the clinical application. Ferulic acid (FA) blocks pSMAD2/3 activation and 
suppresses TGF-β1induced EMT program (65). It might be that specific inhibition of SMAD3, 
as well as stimulation of SMAD7 activities would provide improvements in targeting fibrotic and 
inflammatory tissue responses in the various kidney diseases. Furthermore, SMAD7 might be 
also suitable for treatment of acute kidney injury since it can prevent tubular cell apoptosis. 
However, further studies are warranted to make more conclusive information. 
Moreover, several studies showed protective effects of these therapeutic strategies on the 
podocytes which are mainly affected in kidney diseases with proteinuria. It has been suggested 
that these therapies can even reduce deposition of immune complexes, reverse podocyte injuries 
and prevent interstitial fibrosis as the last stage of many kidney diseases.  
SNAIL 
SNAIL is an attractive target for the development of pharmaceutical agents, especially 
considering that it be induced by numerous factors and signaling involved in EMT. Recently, a 
Co (III)-DNA conjugate, Co(III)-E-box, has been developed for selective inhibition of Snail 




1.4.Fibroblast growth factor receptor (FGFR) and neural cell adhesion 
molecule (NCAM)  
 
1.4.1. NCAM structure  
There are two Neural Cell Adhesion Molecules (NCAMs) in mammals (NCAM1 and NCAM2), 
encoded by two different genes, but here we will focus on NCAM1 because NCAM2 has not 
been widely studied yet. NCAM1 (simply termed as NCAM), also known as CD56, is a cell 
surface molecule encoded by a single gene, located on chromosome 11 in humans. NCAM exists 
in three major isoforms and is also found in soluble secreted form. Three major NCAM isoforms 
result from alternative splicing and are named according to heir molecular weight: NCAM-
120kDa (NCAM-C), NCAM-140kDa (NCAM-B) and 1 NCAM-80kDa (NCAM-A). All of them 
are cell surface molecules, whereby NCAM120 is attached to the cell membrane via a 
glycophosphatidyl inositol (GPI-) anchor while NCAM140 and NCAM180 are single spanning 
transmembrane proteins and differ in the length of their cytoplasmic domains (68-70). 
NCAM belongs to the immunoglobulin (Ig) superfamily and is composed of five extracellular Ig 
domains and two fibronectin type III (FN3) domains and intracellular cytoplasmic part of 
varying length. NCAM gene contains more than 26 exons. The extracellular part of NCAM is 
encoded by exons 1–14 (two exons per module) and is similar for the three major isoforms. 
NCAM180 is defined by additional   16–19exons, while NCAM140 does not include exon 18 
compared to NCAM180. The smallest one isoform (NCAM120), beside common exons 1–14 
contains only additional exon 15 (68-70). 
NCAM molecules can be post-translationally modified either on extracellular or intracellular 
parts. All three isoforms can be extracellularly modified by attachment of long chains of 
polysialic acid (PSA) to the fifth Ig module and the first F3 module. Attachment of the 
negatively charged sugar PSA to the fifth Ig domain influences NCAM adhesive properties, 
changing it form a pro-adhesive to a pro-migratory molecule. Transmembrane isoforms 
(NCAM140 and NCAM180) can be also palmitoylated on intracellular domains (C-terminal 
sites), thereby determining NCAMs association with lipid rafts in the membrane and defining its 
signaling properties (71-74). 
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1.4.2. NCAM functions and signaling pathways 
During embryonic development, NCAM is heavily polysialilated and is widely expressed in 
many organs, including kidneys. However, in the adults it is mainly found in tissues of neural 
origin, but also appears during carcinogenesis. Thus, NCAM is thought be expressed in areas 
which retain a high degree of plasticity. Since during wound healing and repair many cells 
change their phenotype in order to recover injury, it has been considered that induction of 
NCAM expression in such area could appear, especially if in particular organ NCAM is 
expressed during organogenesis. Thus, re-induction of NCAM in epithelial structures could be 
considered as reversed organogenesis, through the process of epithelial to mesenchymal 
transition (EMT) (14, 24-27, 68-74). 
NCAM signaling can be induced by homophilic and various heterophilic interactions with other 
molecules such as fibroblast growth factor receptor (FGFR), heparin, heparan/chondroitin 
sulfates, various types of collagen, glial cell line derived neurotrophic factor (GDNF), GDNF 
family receptor a, ATP, platelet-derived growth factor (PDGF), and various cytoskeletal 
components (24, 69).  
NCAM homophilic interactions 
Precise mechanism of NCAM homophilic binding is not completely clarified and several 
alternative models have been proposed. Since extracellular parts of all three NCAM isoforms 
have Ig-like domains, NCAM's homophilic binding mechanisms involve binding between 
multiple NCAM modules in various configurations (24-27, 68-74). 
Rao et al. suggested that third Ig module of NCAM was important for the NCAM trans-
homophilic binding in the model where the third Ig module binds to itself. They also found that 
the first three modules and can bind to each other, meaning that the third Ig domain binds to 
itself while the second binds to fourth and the first binds to fifth Ig domain (75, 76). However, 
one of the most sensitive methods currently available– NMR and surface plasmon resonance 
(SPR) analysis could not detected proposed interactions. 
Using SPR, NMR and crystallography experiments, binding between the first and second Ig 
modules of NCAM was detected and the importance of the third Ig module for the homophilic 
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binding was also demonstrated. Soroka et al. discovered NCAM/NCAM interactions combining 
the first three Ig modules. Specific interactions between Ig1 and Ig2 modules mediate 
dimerization of NCAM molecules expressed on the same cell surface (cis-interactions), whereas 
interactions between NCAM molecules on the surfaces of opposing cells (trans-interactions) are 
mediated by Ig3 domain and its simultaneously binding to Ig1 and Ig2 (69, 77). 
Signaling cascade stimulated during these homophilic interactions includes NCAM association 
with p59
Fyn
 (Src family kinase) and its subsequent phosphorylation which in turns 
phosphorylates and activates its effector FAK. Activated FAK then acts by inducing CREB (c-
AMP response element binding protein), through Ras/Raf/MAPK/ERK up-stream effectors (78-
80). However, this specific intracellular signaling transduction is attributed only to NCAM-140 
isoform and does not engage NCAM-180 (79). 
This type of signaling cascade promotes adhesion properties of NCAM-expressing cells. 
However, de-adhesion processes can also appear during these NCAM homophilic bindings and 
they are primarily stimulated by post-translational modifications of NCAM molecule by 
polysialic acid (PSA) residues which then interferes with NCAM homophilic interactions (81-
82). 
NCAM and FGFR interactions 
NCAM is also involved in heterophilic interactions and is able to induce FGFR signaling acting 
through this pathway. All NCAM isoforms (120kDa, 140 kDa, 180 kDa) are able to bind to all 
FGFRs (FGFR1-4). The prototypical FGFRs consist of three Ig modules, a transmembrane 
domain and a cytoplasmic tyrosine kinase domain. The Ig1 and Ig2 modules are separated by a 
very long linker containing a stretch of acidic residues, termed the acid box. FGF binding to the 
FGFR results in the receptor dimerization, leading to auto-phosphorylation of the receptor 
tyrosine kinase domains. The FGF-receptor family consing of four closely related receptor 
tyrosine kinases (FGFR 1–4), can be activated their main ligands - FGFs (FGF1–FGF23), and 
also by cell adhesion molecules such as NCAM, L1 and N-cadherin. However, a direct binding 
to the FGFR has only been demonstrated for NCAM. These interactions occur between FN3 
NCAM domain and Ig2 and Ig3 FGFR domains, whereby both FN3 modules of NCAM are 
required for an efficient binding, whilst interaction involving amino acids located in the FG loop 
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region of the second FN3 module of NCAM and the FGFR1 results in weak binding. Beside an 
involvement of Ig2 and Ig3 modeule of FGFR in the interaction with NCAM, acid box region of 
the FGFR is proposed to be also a binding NCAM site but there is no strong evidence of this 
type of interplay. CHD (Cell adhesion molecule Homology Domain) region located in the second 
Ig module of the FGFR has been previously suggested to be involved in binding to NCAM, L1 
and N-cadherin, however despite structural possibility of interaction at this site it has been 
indicated CHD is not necessary for the NCAM/FGFR interaction (83; 69). Molecular sites of 
NCAM/FGFR interactions are illustrated on Figure 3. 
 
 Figure 3. NCAM and FGFR interactions.  
21 
 
After binding to FGFR, NCAM induce its dimerisation and activation through auto-
phosphorylation. Activated FGFR then recruits phospholipase Cγ (PLCγ) cleaving its substrate 
phosphatidylinositol 4,5-bisphosphate (PIP2) and generating the second messenger molecules 
inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 induces the release of Ca
2+
 by 
binding to intracellular Ca2
+
-channels. DAG remains at the membrane and can either activate 
protein kinase C (PKC) or can be converted into 2-arachidonylglycerol (2-AG) and arachidonic 
acid (AA), inducing various downstream signaling events (70, 80). 
Cross-talk between NCAM/NCAM and NCAM/FGFR interactions 
Moreover, cross talk between two NCAM signaling pathways is also possible. Thus, NCAM 
homophilic interactions (inducing p59
Fyn
/FAK) and NCAM heterophilic interaction with FGFR 
can converge at level of ERK activation. Ras-Raf-MAPK-Erk signaling cascade could be 
induced both by NCAM/NCAM and NCAM/FGFR interactions, making difficult to assign ERK 
activation to particular pathway involved in its induction, especially under in vivo observation 






The growing interest in field of renal fibrosis management is reasonable, especially considering 
that the majority of kidney diseases could have chronic course and progressively develop 
impairment of kidney function that is morphologically presented with chronic tubulointerstitial 
damage and fibrosis. For patients and clinicians it is equally important to mellow-down, stop and 
reverse the putative adverse outcomes. Thus, a scientific attempts balancing between beneficial 
and adverse effects of proposed therapies are growing, but often hard to be archived. Further 
investigation should be focused on therapy options which target the underling mechanism of the 
earliest changes observed upon kidney injury. 
Since normal renal interstitium contains scarce fibroblasts, the origin of abundantly observed 
fibroblasts during fibrogenesis brings many controversies and several proposed models are 
available. In addition to rare fibroblasts, scarce NCAM positive cells with spindle shaped or 
dendritic morphology can be detected within the interstitium of the normal adult human kidney 
(16, 85). These cells seemed to have arisen from metanephric mesenchymal cells expressing 
NCAM during kidney development, and selectively persist within the renal interstitium after 
birth (86). Previously, it has been suspected that in early phases of repairing processes of a 
damaged kidney interstitial NCAM+ cells could increase (85). The origin of such NCAM
+
 cells 
in fibrogenesis or kidney repair and their relation to fetal NCAM
+
 mesenchymal cells is still 
unknown and remains to be clarified, as well as their pathophysiological significance. 
Considering an early induction of NCAM expression during fibrogenesis and taking into account 
that its signaling pathway could also involve FGFR activation, we thought that investigation in 
this field could bring new insights into renal fibrosis pathogenesis, especially considering that 
human renal interstitium under fibrotic conditions exhibits highly heterogeneity, mostly with 
regard to molecular markers expressed by interstitial cells (1). Since NCAM is one of the 
receptors essential during kidney organogenesis (86), we would like to clarify whether the 
increase of NCAM
+
 interstitial cell lineage during kidney repair could differ from rare NCAM
+
 
cells situated within normal renal interstitium and if they could share some of the markers 




Moreover, since FGFR1 is involved in fibroblast activation and proliferation and can be 
activated by different ligands including NCAM, the interplay between these molecules is 
required to be clarified during fibrogenesis, mostly due to the fact that activation of FGFR1 by 
NCAM additionally promotes FGFR1 recycling, resulting in sustained FGFR1 signaling that is 








The following aims were purposed: 
 Explore quantitative relationship between NCAM expressing renal interstitial cells with 
the degree of renal interstitial fibrosis and underlying pathohistological diagnosis, using 
human kidney biopsy samples 
 Investigate molecular profile (including the presence of proteins and defining the mRNA 
levels) of NCAM expressing renal interstitial cells with regard to three NCAM isoforms 
(NCAM-120, NCAM-140, NCAM-180), molecules whith regulatory role in renal fibrosis 
(FGFR1, HE4, α-SMA, MMP-2, MMP-9, SLUG, SNAIL, BMP 7, ALK 3), as well as 
molecules involved in TGF-β signaling pathway (SMAD2, SMAD3) 
 Compare mRNA expression levels of NCAM, FGFR1, ITGA5, ITGB1, RUNX1 and 
RUNX1T1 between kidney tissue samples of different degrees of interstitial fibrosis, and 
also compare it among various pathohistological diagnosis 
 Define the involvement of TGF-β in cell migration and explore its impact on molecular 
profile and dynamics of gene expression changes in TGF-β treated tubular epithelial cells 
(HK-2 cell line), both in the presence and the absence of FGFR inhibitor (PD173074), 
comparing with control (non-treated) HK-2 cells; investigate NCAM isoforms (NCAM-
120, NCAM-140, NCAM-180), FGFR1 and FGFR2 (their IIIb and IIIc isoforms), SLUG, 
SNAIL, TWIST 1, MMP-2, MMP-9, RUNX1, RUNX1T1, N-cadherina, E-cadherina, 




3. MATERIAL AND METHODS 
3.1.Human kidney samples 
The study was carried out in accordance with the Code of Ethics of the World Medical 
Association (Declaration of Helsinki) and was approved by the Ethic Committee of Medical 
Faculty University of Belgrade (approval no. 29/II-15). 
In order to explore quantitative relationship between NCAM expressing renal interstitial cells 
with the degree of renal interstitial fibrosis and underlying pathohistological diagnosis, as well as 
to perform further characterization of NCAM expressing cells, 93 biopsy specimens of various 
kidney diseases were included in this study after routine diagnostic procedures. 
Moreover, additional 50 kidney biopsies of patients clinically presented with nephrotic syndrome 
or isolated proteinuria were analyzed in order to investigate clinicopathological features 
comparing them with the presence and expression pattern of TGF-β signaling pathway 
downstream effectors (SMAD3, SMAD2, SNAIL). 
For the assessments of gene expression, mRNA was isolated from the rest of frozen tissues of 24 
patients. Relative mRNA levels were analyzed according the degree of renal interstitial fibrosis 
among heterogeneous diagnosis.  
Renal tissue from the first core needle biopsy of each patient was formalin-fixed, paraffin-
embedded, routinely stained with H&E, PAS, silver methenamine and Masson trichrome, and 
further used for immunohistochemistry. The second renal biopsy core was put into cell culture 
medium RPMI 1640 (PAA Laboratories GmbH, Austria) immediately after removal, snap-frozen 
in liquid nitrogen, used for routine immunofluorescent diagnosis, and the rest of the tissue stored 
at -80
o
C for further immunostaining. In the cases where we had enough tissue, a piece of tissue 
sample was conserved in RNAlater (Qiagen Ltd., Hilden, Germany), a RNA stabilization 
reagent, for subsequent efficient reverse transcriptase PCR (RT-PCR) analysis. Normal renal 
tissues were obtained from 10 cadaveric kidneys that were not transplanted, as well as from 10 




3.1.1. Patients data 
Clinical and laboratory patients data recorded at the time of biopsy, as well as at the time of last 
medical examination were collected from the medical records. Patients were clinically classified 
in chronic kidney disease (CKD) stages, following the widely accepted recommendations (87). 
Follow-up period was also noted in order to perform survival analysis aimed to define predictors 
of disease progression.  
3.1.2. Assessment of interstitial renal fibrosis and tubular atrophy 
Extension of interstitial renal fibrosis (IRF) was semi-quantitatively assessed on biopsies stained 
with PAS and Massone-trichrome, applying a scale from 0 to 3 with 0 meaning no IRF, 1 – less 
than 25% of renal tissue with IRF, 2 - 25% to 50% of renal tissue with IRF, and 3 - more than 
50% of renal tissue with IRF. Using the same rule, the abundance of tubular atrophy (TA) was 
assessed (TA-0 – no tubular atrophy; TA-1 – less than 25% of atrophic tubuli; TA-2 – 25-50% of 
atrophic tubuli; TA-3 – more than 50% of atrophic tubuli).    
3.1.3. Immunohistochemistry 
Immunohistochemistry was performed both on paraffin and cryo sections. Tissues embedded in 
paraffin blocks are previously fixed in 4% formalin and dehydrated in alcohol. Thus, before 
proceeding to staining procedures, 5 μm kidney tissue sections from paraffin blocks were 
deparaffinized in xylene and rehydrated through decreasing alcohol percentage series (100%, 
96% and 70%) finished with washing step into distillated water. Five μm thick frozen sections 
cut from each tissue were fixed in acetone for 10 min, air-dried at room temperature for 1 hour. 
Heat-induced antigen retrieval was performed for 20 min either in low (pH 6.0) or in high pH 
(pH 9.0) buffers, depending on the antibody. After antigen retrieval both frozen and paraffin 







Table 3.1. List of primary antibodies used for immunohistochemistry in human kidneys.  
No. Primary antibody (clone) Source Dilution Manufacture (Cat. No.) 
1 NCAM (Eric-1) Mouse  1:100 Ancell Corporation (208-020) 
2 NCAM (123C3.D5) Mouse RTU LabVision (MS-204-R7) 
3 MMP2  Rabbit 1:50 Sigma-Aldrich (HPA001939) 
4 MMP9 Rabbit 1:50 Sigma-Aldrich (HPA001238) 
5 SMAD2 (clone 31H15L4) Rabbit 1:100 Thermo scientific (700048) 
6 SMAD3 (clone EP568Y) Rabbit 1:500 Abcam (ab40854)  
7 SNAIL Rabbit 1:100 Abcam (ab180714) 
NCAM (Eric-1) was used on cryostat samples, while paraffin samples were incubated with 
NCAM (123C3.D5). The EnVision
TM
 Detection System (Dako) was applied to label anti-mouse 
or anti-rabbit polymer. Visualization of antigen-antibody reaction was carried out by 3,3'-
diaminobenzidine (DAB) or 3-amino-9-ethylcarbazole (AEC) and subsequently counterstaining 
with hemalaun (Merck, USA). Specimens were mounted with non-aqueous permanent mounting 
medium (Ultramount, Dako) or with aqueous-based mounting medium (Faramount, Dako). 
Controls were performed as previously described (85), and for mouse monoclonal antibodies as 
isotype control mouse IgG1 (ab91353, Abcam, UK) antibody was also used. Slides were 
evaluated using the light microscope BX53 with DP12 CCD camera (Olympus, Germany). 
3.1.3.1. Semi-quantification of NCAM interstitial positivity 
Examining the relationship of NCAM
 
expressing interstitial cells with degree of interstitial renal 
fibrosis (IRF), immunostaining was performed on paraffin sections and evaluated by light 
microscopy, as a number of positive cells per field of view on the magnification x400 in the 
region with the most extensive interstitial NCAM positivity in a biopsy core.  20 cases of normal 
renal tissue were also assessed for the number of NCAM positive cells within the interstitium. 






3.1.4.  Double immunofluorescence labeling 
Five μm-thick cryostat sections were treated as previously described (85). In brief, frozen section 
were dried for 1h at room temperature, and fixed in acetone for 10 min. Since NCAM 
(EP2567Y) was produced in rabbit, it was used for double immunofluorescent labeling when the 
second antibody originated from mouse. 
Thus, in order to obtain double fluorescent labeling NCAM/granzyme B, NCAM/αSMA cells 
and NCAM/MMP9, we applied rabbit monoclonal antibody against NCAM clone EP257Y, 
followed by Cy3- conjugated goat anti-rabbit antibody (1:2000, Dianova), and mouse 
monoclonal antibodies against granzyme B, αSMA or MMP9 were added followed by goat anti-
mouse IgG-Alexa 488 (1:1000, Invitrogen). For NCAM/HE4 and NCAM/EPO cells detection, 
mouse monoclonal NCAM/Eric-1 antibody followed by goat anti-mouse IgG-Alexa 488, and 
rabbit polyclonal HE4 antibody, as well as rabbit polyclonal anti-EPO, followed by Cy3-
conjugated goat anti-rabbit antibody were applied. Nuclei were identified by 4,6-diamino-2-
phenylindolyl-dihydrochloride (DAPI; 1 μg/ml). List of primary antibodies with corresponding 
dilutions is shown in Table 3.2. 
Table 3.2. List of primary antibodies used for immunofluorescence in human kidneys.  
No. Primary antibody (clone) Source Dilution Manufacture (Cat. No.) 
1 NCAM (Eric-1) Mouse  1:100 Ancell Corporation (208-020) 
2 NCAM (EP2567Y) Rabbit 1:200 Epitomics (2433-1) 
4 MMP9 Mouse 1:100 Calbiochem 
6 MMP24 Rabbit 1:100 Calbiochem 
9 α-SMA (1A4) Mouse 1:400 Dako 
10 Granzyme B (2C5) Mouse 1:50 Santa Cruz (sc-8022) 
11 EPO Rabbit 1:100 Abcam (ab126876)  
12 HE4 Rabbit 1:100 Abcam (ab85179) 
13 CD73 Mouse 1:50 Abcam (ab81720) 
For assessment of TGF-β signaling and relation to molecules involved in EMT or fibrosis, the 
following stainings were performed:  pSMAD2/MMP2, pSMAD3/MMP9, SNAIL/α-SMA, 
TWIST/N-cadherin. Antibodies dilutions and detail are shown in Table 3.3. 
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Table 3.3. List of primary and secondary antibodies used for immunofluorescence in 
human kidneys.  
Primary antibodies Source Dilution Manufacturer 
P-Smad3 (9520S) rabbit 1:100 Cell Signaling 
p-Smad2 (3108S) rabbit 1:100 Cell Signaling 
MMP-2 (sc-13594) mouse 1:50 Santa Cruz 
MMP-9 (sc-393859) mouse 1:50 Santa Cruz 
Twist1 (ABD29) rabbit 1:100 EMD Millipore 
SNAIL (ab180714) rabbit 1:100 Abcam 
Alpha-SMA (A5228) mouse 1:100 Sigma 
N-Cadherin (610920) mouse 1:50 BD Transduction Laboratory 
HIF-1α (hydroxy P402) (ab72775) rabbit 1:50 Abcam 
HIF-2α (ab109616) rabbit 1:100 Abcam 
Secondary antibodies    
Anti-mouse IgG (H+L), Alexa Fluor 594 (A21203) donkey 1:200 Life technologies 
Anti-rabbit IgG (H+L), Alexa Fluor 488 (A21206) donkey 1:200 Life technologies 
Controls were performed in all experiments as previously described (85). Sections were mounted 
with Fluoro Preserve Reagent (Calboichem, Germany). Slides were analyzed either on LSM 510 
Confocal Microscope with Apotome (Carl Zeiss, Germany) using the AxioVision Release 4.8.2 
(Carl Zeiss, Germany) software version for analysis and documentation, or on epifluorescence 
microscopy with F-View CCD camera (Olympus, Germany), whereby digital pictures of each 
fluorescence channel were taken and superimposed for the specific antibody staining using the 








3.1.5. Laser capture microdissection, RNA isolation and quantitative real-time reverse 
transcription PCR  
Frozen renal tissues obtained from normal kidneys and from biopsies with incipient IRF were 
stained with NCAM/Eric-1 antibody. Only NCAM
+
 cells localized within renal interstitum 
exhibiting dendritic morphology were marked for catapulting in laser capture microdissection 
(LCM) procedure. Between 35 and 50 NCAM
+
 cells were captured from each sample using 
PALM MicroBeam (Zeiss, Germany) and afterward stored on -80°C in microtubes with 100μl 
RNAlater reagent until further analysis. 
RNA isolation was carried out using Arcturus® PicoPure® RNA isolation kit (Applied 
Biosystems, Germany), suitable for high quality RNA extraction from small samples. 
The quality of the isolated RNA was assessed using NanoDrop 2000 spectrophotometer (Thermo 
Scientific, Germany). 50 ng of total RNA was digested with DNaseI (Sigma) and used for cDNA 
synthesis using SuperScript II Reverse Transcriptase (Life Technologies). For quantitative real-
time reverse transcription PCR (qRT-PCR) analysis, diluted cDNA (1/10) was used as a template 
in a Fast SYBR Green Master Mix (Life Technologies, Germany) and run in StepOnePlus™ 
Real-Time PCR System (Applied Biosystems) in a total reaction volume of 20 μL. Primers were 
designed and purchased from PrimerDesign. Primer sequences are shown in Table 3.4. Samples 
were run in triplicates and the mRNA expression levels were quantitatively analyzed and 
normalized to the level of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) housekeeping 
gene. Before decision to use GAPDH as housekeeping gene in qRT-PCR procedure, we also 
tested 18s and β-actin. As signals for GAPDH were the most consistent within the analyzed 
samples we used it further analyses in qRT-PCR. GAPDH primers are also provided by 







Table 3.4. Primer sequences used for qRT-PCR procedures. 
 
 
Forward primer 5’ to3’ Reverse primer 5’ to3’ 
NCAM-120 GAACCTGATCAAGCAGGATGACGG CTAACAGAGCAAAAGAAGAGTC 
NCAM-140 GTCCTGCTCCTGGTGGTTGTG CCTTCTCGGGCTCCGTCAGT
  
NCAM-180 CGAGGCTGCCTCCGTCAGCACC CCGGATCCATCATGCTTTGCTCTC 
FGFR1 GGCTACAAGGTCCGTTATGCC GATGCTGCCGTACTCATTCTC 
FGFR1 IIIb AATGTGACAGAGGCCCAGAG GGAGTCAGCAGACACTGT 
FGFR1 IIIc ACTGCTGGAGTTAATACCAC GGAGTCAGCAGACACTGT 
FGFR2 GCGTTTTCCTTGCAGCGGCTGG GTAAGTCACAGGATTCCCGTC 
FGFR2 IIIb CACTCGGGGATAAATAGTT ACTCGGAGACCCCTGCCA 
FGFR2 IIIc CGGTGTTAACACCACGGAC ACTCGGAGACCCCTGCCA 
WFDC2 (HE4) AGAACTGCACGCAAGAGTG TTGAGGTTGTCGGCGCATT 
α-SMA AAGCACAGAGCAAAAGAGGAAT ATGTCGTCCCAGTTGGTGAT 
FSP-1 TCTTTCTTGGTTTGATCCTG GCATCAAGCACGTGTCTGAA 
SLUG ACTCCGAAGCCAAATGACAA CTCTCTCTGTGGGTGTGTGT 
SNAIL GGCAATTTAACAATGTCTGAAAAGG GAATAGTTCTGGGAGACACATCG 
TWIST CTCAAGAGGTCGTGCCAATC CCCAGTATTTTTATTTCTAAAGGTGTT 
MMP2 TACAGGATCATTGGCTACACACC GGTCACATCGCTCCAGACT 
MMP9 TGTACCGCTATGGTTACACTCG GGCAGGGACAGTTGCTTCT 
ALK3 GGACATTGCTTTGCCATCATAG GGGCTTTTGGAGAATCTTTGC 
BMP7 CCTCCATTGCTCGCCTTG TATGCTGCTCATGTTTCCTAATAC 
ITGA5 GGCTTCAACTTAGACGCGGAG TGGCTGGTATTAGCCTTGGGT 
ITGB1 GTAACCAACCGTAGCAAAGGA TCCCCTGATCTTAATCGCAAAAC 
E-cadh CATGAGTGTCCCCCGGTATC CAGTATCAGCCGCTTTCAGA 
N-cadh TCAGGCGTCTGTAGAGGCTT ATGCACATCCTTCGATAAGACTG 
RUNX1 TGAGCTGAGAAATGCTACCGC ACTTCGACCGACAAACCTGAG 
RUNX1T1 ATGCCAGACTCACCTGTGGAT GGCTGTAGGAGAATGGCTCG 








3.2.Cell culture (HK-2 cells) 
3.2.1. Experimental procedure 
Human proximal tubular epithelial cells (HK-2 cell line) were cultured in 6-well plates in 2ml of 
growing medium (DMEM medium supplemented with 10% FCS and 1% 
penicillin/streptomycin) at 37°C in 5% CO2 air. They were seeded in the concentration of 
4×10
4
/ml of medium. Next day, growing medium was removed and serum-free DMEM was 
added. Experimental procedures started on the third day (24h after starvation) and completely 
were conducted under serum-free conditions. HK-2 cells were seeded in 4 wells divided in 
control, TGF-β1, PD173074, and TGF-β1+PD173074 treated groups. HK-2 cells were treated 
with 100nM PD173074 (Santa Cruise, CAS 219580-11-7) and stimulated with recombinant 
human TGF-β1 (R&D Systems) in the concentration of 10ng/ml. Treatment with PD173074 was 
done 1h prior to TGF-β1 stimulation. Cells were monitored by light microscopy at different time 
point, depending on the further experimental procedures. 
3.2.2. Scratch assay 
In order to estimate cell migration capacity in 4 experimental groups, we made scratches in the 
wells (in 6-well plate) using 1000μl pipette tips. Scratch was done immediately prior to TGF-β1 
stimulation. Distance between cells separated with the scratch was measured under the 
microscope, using Olympus XM10 camera and cellSence software (under the 10x 
magnification), at three distinct points which were labeled in order to repeat measurements at the 
same points later. Measurements were repeated 24, 48 and 72 hours after TGF-β1 application.  
3.2.3. RNA isolation and real-time RT-PCR analysis 
Cells were detached using trypsin and after washing with PBS they were centrifuged. Cell pellet 
was used for RNA isolation which was carried out using TRIzol reagent (Invitrogen) and 
PureLink® RNA Mini Kit (Life Technologies) following manufacturer instructions. The quality 
of the isolated RNA was assessed using NanoDrop 2000 spectrophotometer (Thermo Scientific). 
100 ng of total RNA, digested with DNaseI (Sigma), was used for cDNA synthesis using 
SuperScript II Reverse Transcriptase (Life Technologies). For quantitative real-time reverse 
transcription PCR (qRT-PCR) analysis, diluted cDNA (1/10) was used as a template in a Fast 
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SYBR Green Master Mix (Life Technologies) and run in StepOnePlus™ Real-Time PCR 
System (Applied Biosystems) in a total reaction volume of 20 μL. Primer sequences are shown 
in Table 3.4. Samples were run in triplicates and the mRNA expression levels were 
quantitatively analyzed and normalized to the level of glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) housekeeping gene. GAPDH primers are provided by PrimerDesign, 
but the sequences are undisclosed. RNA isolation and qRT-PCR were done, depending on the 
genes of interest, at several time points: 6, 12, 24, 48 and 72 hours after TGF-β1 stimulation.  
3.2.4. Double immunofluorescence 
On the first day, 10
4
 HK-2 cells resuspended in 500µL of growing medium were seeded in 8 well 
culture slides (Falcon® 8 Well culture slide, glass slide with polystyrene vessel, Product 
#354118). Next day starvation was performed by removing the growing medium and changing 
into serum-free DMEM. On the third day experiment started, as described. After finishing the 
experimental procedures, immunofluorescent staining was performed as follows. Medium was 
removed from the chamber slides and slides were briefly washed with PBS. Then, -20°C pre-
cold 100% methanol was added in each well and culture slides were put on -20°C for 20min. 
When removed from -20°C, methanol was discarded and slides were washed briefly with PBS, 
preparing the slides for permeabilization step which was performed with 0.2% Triton X-100 in 
PBS for 15min at RT°. After 2 times washing with PBS, blocking with 5% BSA dissolved in 
0.1% Tween 20 in PBS was performed for 1h at RT°. Next, slides were washed with PBS and 
afterwards incubated with primary antibodies overnight on 4°C (two primary antibodies of 
different sources, i.e. one rabbit and one mouse or goat). Antibodies were diluted in 1% BSA 
dissolved in 0.1% Tween 20 in PBS and details are summarized in the Table 3.5. The second day 
of immunofluorescent staining started with washing step (3x5min with 0.1% Tween 20 in PBS 
on shaking plate) followed by application of secondary antibodies for 1h at RT°. Afterwards 
slides were washed 2 times for 5 min with 0.1% Tween 20 in PBS on shaking plate and prepared 
for incubation with DAPI (1:1000 diluted in pure PBS) on RT° for 5min. Chambers were 
removed and slides were finally washed with PBS for 15 min on shaking plate and covered using 




Table 3.5. List of primary and secondary antibodies used for cell culture double 
immunofluorescent staining. 
Primary antibodies Manufacturer Source Dilution 
P-Smad3 (9520S) Cell Signaling rabbit 1:100 
p-Smad2 (3108S) Cell Signaling rabbit 1:100 
Ki-67 (9449S) Cell Signaling mouse 1:200 
Twist1 (ABD29) EMD Millipore rabbit 1:100 
SNAIL (ab180714) Abcam rabbit 1:100 
Alpha-SMA (A5228) Sigma mouse 1:100 
Vimentin (AB1620) EMD Millipore goat 1:20 
N-Cadherin (610920) BD Transduction Laboratory mouse 1:50 
Secondary antibodies    
Anti-mouse IgG (H+L), Alexa Fluor 594 (A21203) Life technologies donkey 1:200 
Anti-rabbit IgG (H+L), Alexa Fluor 488 (A21206) Life technologies donkey 1:200 

















Statistical analysis was performed using the IBM SPSS software, version 20.0. Each numerical 
variable was tested for normality of distribution, using Shapiro–Wilk and Kolmogorov–Smirnov 
tests, as well as considering skewness and kurtosis before the decision of implementation 
parametric or nonparametric statistical tests. For the assessments numerical data differences 
between two groups, Student t-test or Mann-Whitney U were applied depending on the normality 
of data distribution. ANOVA was used for the assessment of numerical data among more than 
two groups, only if Levene’s test of homogeneity of variances allowed it (p>0.050), otherwise 
Kruskall-Wallis test, followed by Mann-Whitney U were applied. Correlations between 
numerical variables are analyzed by Pearson’s (if data followed normal distribution) or 
Spearman’s correlation (if data did not follow normal distribution). Nominal/ordinal data are 
analyzed by χ2 test or Fisher exact test or by Kruskall-Wallis test, followed by Mann-Whitney U, 
depending on the number of groups. Univariate analysis was performed using the Kaplan–Meier 
estimator in order to identify variables significantly associated with adverse outcome. 
Differences between two groups of patients (with and without adverse outcome) were assessed 
by two-sided log rank test. In univariate analysis, potential predictors of kidney dysfunction 
development were identified using a significance value of p<0.05. P values <0.05 were also 










4. RESULTS  
4.1.NCAM expressing renal interstitial cells and renal fibrosis 
Renal interstitial NCAM
+
 cells were rarely present in the tubulointerstitial compartments of 
normal human kidneys, used as a control group (Fig. 4.1.1). However, in 93 paraffin-embedded 
biopsy specimens with various degrees of interstitial fibrosis, NCAM
+
 interstitial cells were seen 
in 58 cases (62.4%). NCAM
+
 interstitial cells were detected in 100% of MesPGN, 76.0% of LN, 
69.2% of MGN,  62.5% of MPGN, 61.1% of FSGS, 50% of IgA nephropathy, 33.3% of renal 
grafts, 25% of RPGN, while NCAM
+
 interstitial cells were not detected in 4 cases of minimal 
change disease (Fig. 4.1.1). 
 
Figure 4.1.1. Frequency of interstitial NCAM positivity among various kidney diseases and 
in control normal kidneys. 
Mean number of NCAM
+
 cells were significantly higher in diseased kidneys (mean 2.45 
NCAM
+
 cells, 95% CI (1.83-3.07)) compared to controls (mean 0.25 NCAM
+
 cells, 95% CI 
(0.4-0.46)), t=6.731; p<0.001. 
A statistically significant increase of NCAM
+
 interstitial cells was present in incipient IRF, 
assessed as scale 1, compared to all others scales of fibrosis independently of the 




Figure 4.1.2. NCAM and severity of renal fibrosis. Number of detected NCAM
+
 cells per field 
of view on ×400 magnification in controls and in diseased kidneys with regard to severity of 
interstitial renal fibrosis (IRF); p values after applying Mann-Whiteny U test. 
 
Relationship between number of NCAM
+
 cells and underlying kidney diseases classified 
according to IRF stages was further analyzed (Table 4.1.1.), however, there were no significant 
differences. These data support our previous findings that increase of interstitial NCAM
+
 was 
independent of diagnosis, but depends only on extent of interstitial fibrosis, appearing almost 









Table 4.1.1. Distribution of diagnosis and neural cell adhesion molecule (NCAM) 
interstitial positivity (including the number of NCAM positive interstitial cells presented 
with mean ±SD) observed among stages of interstitial renal fibrosis (IRF). 
Diagnosis 





























































































FSGS 6 (3/6) 0.8±1.2 11 (8/11) 3.6±3.6 1 (0/1) 0.0±NA - - 
Kidney graft - -   3 (2/3) 3.0±3.0 1 (1/1) 2.0±NA 5 (0/5) 0.0±0.0 
MGN 7 (4/7) 1.0±1.2   4 (4/4) 6.5±4.4 - - 2 (1/2) 1.5±2.1 
Lupus nephritis 5 (2/5) 0.6±0.9 13 (12/13) 5.3±3.3 6 (4/6) 3.5±3.8 1 (1/1) 1.0±NA 
MesPGN 1 (1/1) 2.0±NA   4 (4/4) 3.8±1.7 - - - - 
MPGN 2 (1/2) 0.5±0.71   3 (3/3) 3.7±2.1 3 (1/3) 1.7±2.9 - - 
Minimal changes 4 (0/4) 0.0±0.0 - - - - - - 
IgA nephropathy 4 (2/4) 0.5±0.6   1 (1/1) 4.0±NA 1 (0/1) 0.0±NA - - 
RPGN - - - - 1 (0/1) 0.0±NA 4 (3/4) 0.8±0.5 









N- number of cases; *- mean number of NCAM+ cells per field of view x400; NA- not applicable; #- ANOVA test 
was applied; ##- Kruskall-Wallis test was applied because Levene’s test of homogeneity of variances was <0.050 
and consequently ANOVA could not be used. 
Fig. 4.1.3., panel A illustrates routine PAS staining with diffuse incipient renal fibrosis (IRF-1) 
of patient with FSGS. Applying immunohistochemical staining, within the same area many 
peritubular NCAM
+
 cells were detected in the interstitial compartment (panel B).  
However, NCAM
+
 interstitial cells were usually detected focally around tubuli in the area with 





Figure 4.1.3. Morphology of interstitial fibrosis and NCAM interstitial positivity. FSGS 
with slight interstitial fibrosis (IRF-1) without tubular atrophy exhibiting an increased diffuse 
NCAM interstitial positivity detected on slides from paraffin-embedded tissue. (A) PAS, x400. 
(B) Immunoperoxidase staining, NCAM clone 123C3.D5, x400. 
 
 
Figure 4.1.4. Lupus nephritis with NCAM 
positive interstitial cells detected focally 
around tubuli in the area with slight IRF 
(IRF-1). (A) PAS, x400. (B) Massone 
trichrome staining, x400. (C) 





4.2.Molecular profile of NCAM expressing renal interstitial cells 
Since NCAM expressing renal interstitial cells were detected in early fibrosis, we performed 
several double immunolabelings aimed to better define molecular characteristics of these cells, 
especially with regard to their regulatory role in fibrosis. 
Previous studies at our Institute reveled some of the markers that NCAM+ interstitial cells could 
share, such as FGFR1 and α5β1 integrin. These two markers are known to be expressed by 
fibroblasts. Thus, we further consider an opportunity to see whether these cells could represent a 
population of activated fibroblasts, so-called myofibroblasts. Beside α-SMA, HE4 expression is 
newly established characteristic of some myofibroblasts. 
Despite widespread interstitial expression of both NCAM and α-SMA in many cases with early 
fibrosis, the overlapping of these two molecules did not appear albeit sometimes it looked 
possible. Although both NCAM and α-SMA were localized within the same compartments, they 
did not expressed by the same cells. Moreover, NCAM+ and α-SMA+ interstitial cells 
represented two distinct cell populations, as illustrated on Fig. 4.2.1. 
 
Figure 4.2.1. NCAM and α-SMA double immunolabeling.  
CD73 has been previously characterized as marker of some population of renal fibroblasts, 
including those with EPO producing features. Here we examined if NCAM positive renal 
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interstitial cells could express CD73, and despite abundant expression of both NCAM and DC73 
in the renal interstitial compartment in cases with incipient fibrosis, co-expression was found 
only in few interstitial cells (Fig. 4.2.1).  
HE4 was also expressed by renal interstitial cells. In normal, control kidneys HE+ interstitial 
cells were rare. It was not surprising, because fibroblasts are consider to be scant in normal 
interstitium. However, we detected some overlapping between HE4 and NCAM that is also 
rarely present in normal renal interstitium. Furthermore, in the cases of incipient renal fibrosis, 
where NCAM+ cells could be prominent, HE4 was more frequently detected in the same cells as 
NCAM. HE4 and NCAM double immunolabeling is presented on the Fig. 4.2.2.      
 
 
Figure 4.2.2. NCAM and HE4 double immunolabeling.  
Modulation of fibrotic tissue response partly depends on the time-dependant activity of various 
tissue proteases, such as MMPs. Galatinases (MMP2 and MMP9) are the most popular in renal 
pathology. Their substrate is mainly collagen type IV, thus, their enhanced activity is noted in 
tubular epithelium affecting the integrity of basal membrane. Indeed, in this step their activity is 
considered as undesirable. However, if fibrosis is already initiated, activity of these gelatinases in 
the interstitial compartment would be useful to protect kidney tissue from the excessive ECM 
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deposition. Since NCAM+ interstitial cells are present in early fibrosis, we further investigated 
their relation with MMP2 and MMP9. Interestingly, MMP2 was not detected in the interstitium, 
but was abundantly expressed in tubuli usually surrounded with fibrosis. Nevertheless, MMP9 
was sometimes expressed by glomerular basement membrane components and was rarely found 
in the interstitium. Sometimes MMP9 was found in interstitium in the NCAM expressing cells, 
implicating some capacity of NCAM+ cells to degrade ECM in fibrosis. MMP24 was observed 
diffusely in tubular basement membrane in the cases with increased interstitial NCAM 




Figure 4.2.3. NCAM, MMP2, MMP9 and MMP24 immunolabeling. 
At the beginning of our research, we found that increased interstitial NCAM positivity, appeared 
in incipient IRF, was independent of the underlying kidney diseases, although we cannot exclude 
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that increase in number of NCAM
+
 interstitial cells was caused by hypoxia at least in some 
cases. In this setting, since erythropoietin (EPO) producing renal fibroblasts are expected to 
increase rapidly in response to tissue hypoxia [5, 21], double immunofluorescent labeling using 
EPO and NCAM antibodies was performed. Unfortunately, we were not able to detect any EPO 
and NCAM overlapping (Figs. 4.2.4. A-C). Since NCAM can be also expressed by natural killer 
(NK) cells of the innate immune system, double NCAM/granzyme B immunostaining was 
performed to clarify their relationship in incipient renal fibrosis. In the panel D, an area of 
diffuse NCAM interstitial staining is visible without any granzyme B positivity. Within the 
whole biopsy sample of the same case that belongs to FSGS with incipient IRF only a single 
interstitial cell expressed both NCAM and granzyme B (panel E). Among cases of lupus 
nephritises, overlapping between these two molecules has not been detected, even within areas of 
mononuclear interstitial infiltrates (panel F). Thus, there were interstitial NCAM
+
 cells different 
from NK cells that were almost exclusively increased in incipient renal fibrosis.  
 






Since tissue lysates could contain other NCAM expressing cells, not only the interstitial spindle 
shaped NCAM
+
 cells which were within the focus of our study, we decided to perform laser 
capture microdissection (LCM) which allowed us to separate and collect pure cell populations of 
the relevant NCAM
+
 cells out of tissue samples. Isolated pure NCAM
+
 cell populations were 
the most suitable starting material for downstream quantitative real-time PCR (qRT-PCR). Fig. 
4.2.5. (panels A and B) represents renal tissues stained with anti-NCAM antibody prior to LCM 
procedure, and illustrate widespread NCAM expression in incipient IRF (panel A) and scarce 
NCAM positivity in normal renal interstitium (panel B). Panels C-E illustrate tissues after LCM 
procedure. Statistically significant changes in the relative mRNA expression levels of NCAM 
isoforms have been revealed after applying qRT-PCR in the pure NCAM
+
 cell population. 
NCAM
+





 cells in normal kidneys, p=0.004 (panel F). Nevertheless, mRNA 




 isoforms were not changed significantly in 





were slightly up-regulated under fibrotic conditions. These findings implicate a 
specific NCAM isoform switch during fibrogenesis, thereby suggesting diverse roles of NCAM 




Figure 4.2.5. Isolation of NCAM positive renal interstitial cells by laser capture 
microdissection (LCM) and changes in relative mRNA NCAM isofroms expression levels in 
incipient renal fibrosis. (A) Slide performed on cryostat section and stained by NCAM, clone 
Eric-1, with widespread NCAM expression, prior laser capture microdissection (arrow indicates 
the first selected NCAM positive cell for further LCM, while arrowhead shows second selected 
area). (B) Slide with rare NCAM cells within normal interstitium prior LCM.  (C), (D) and (E) 
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the same slides as Fig. (A) and (B) after LCM procedure.  (F) Relative expression levels of 
NCAM mRNAs isoforms, determined by quantitative real-time PCR (qRT-PCR), in NCAM
+
 
cells captured by LCM from normal and from renal tissue with incipient IRF, data are presented 
with mean values and standard error bars; due to high variability of variables, exclusively in 
diseased kidneys, nonparametric Mann Whitney U test was applied to assess the difference in 
mRNA levels between controls and diseased kidneys; there were 6 samples (2 cases in 
triplicates) of control cases and 42 (14 cases in triplicates) samples of cases with incipient renal 
fibrosis. 
4.3.Clinical relevance of NCAM expressing renal interstitial cells 
NCAM expressing renal interstitial cells has been detected within 59.4% human kidney biopsy 
samples, independently of the underling pathohistological diagnosis (p=0.995). However, it has 
been confirmed that frequency of NCAM positivity was higher in early stage of renal interstitial 
fibrosis, compared to other stages (Table 4.3.1). There were no significant difference of the 
distribution of NCAM expressing cases with regard to CKD stage, neither at the time of biopsy 
(p=0.954) nor at the time of last medical examination (p=0.601), as shown in the Tables 4.3.2 
and 4.3.3. However, it has been noticed that patients without NCAM expressing renal interstitial 
cell had higher serum creatinine values compared to patients with NCAM positivity (Table 4.3.2 
and 4.3.3), although it did not reach statistical significance. Nevertheless, proteinuria was lower 
in patients whose biopsies revealed interstitial NCAM positivity (3.97 g/24h) than in patients 
without NCAM expressing renal interstitial cells (8.41 g/24h) (p=0.024).  
These patients were also followed for 16 months (mean value). Pathohistological and clinical 
parameters were used in Kaplan-Meier survival analysis in order to define predictors of 
progression to advanced CKD stages. Among them, pathohistological diagnosis (p=0.026) and 
the degree of renal interstitial fibrosis (p=0.002) were marked as predictors of adverse outcome. 
Thus, patients with minimal change disease did not progress to advanced CKD stages, as 
illustrated on Fig.4.3.1.A. On the same Figure, panel B shows the impact of interstitial fibrosis 
degree on the CKD progression. Therefore, 90% of patients without fibrosis preserved kidney 
function during 3 years of follow-up, while patients with fibrosis exhibited deterioration of 
excretory kidney function with increasing incidence and faster appearance in advanced IRF 
stages (Fig.4.3.1.B). The presence of NCAM expressing renal interstitial cells (Fig.4.3.1.C) did 
not affect long-term patients outcome (with regard to CKD stages), p=0.273.  Possibility of 
progression to advanced CKD stages depended on the clinical parameters, such as serum 
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creatinine (p<0.001) and urea (p=0.007) values. Kidney function was maintaining longer in 
patients with normal serum creatinine and urea values compared to the patients with elevated 
aforementioned values (Fig.4.3.1.D and E). Worse outcome was observed slightly faster in 
patients with proteinuria >3g/day (Fig.4.3.1.F), however without statistical significance 
(p=0.231).  
Table 4.3.1. Distribution of patients with NCAM expressing renal interstitial cells with 
regard to pathohistological variables.  
Pathohistological variables 




FSGS 5 (38.8%) 8 (61.5%) 
0.995 
Kidney graft 5 (71.4%) 2 (28.6%) 
MGN 4 (33.3%) 8 (66.7%) 
LN 5 (31.2%) 11 (68.8%) 
MesPGN 0 (0.0%) 4 (100.0%) 
MPGN 2 (33.3%) 4 (66.7%) 
MCD 3 (100.0%) 0 (0.0%) 
IgA nephropathy 2 (66.7%) 1 (33.3%) 
RPGN 2 (40.0%) 3 (60.0) 
Stage of interstitial renal fibrosis (IRF) 
IRF - 0  14 (70.0%) 6 (30.0%) 
0.001* 
IRF - 1 4 (13.8%) 25 (86.2%) 
IRF - 2 4 (44.4%) 5 (55.6%) 





Table 4.3.2. Clinical and laboratory parameters recorded at the time of biopsy in patients 
with and without NCAM expressing renal interstitial cells. 
Clinical and laboratory parameters recorded at the 
time of biopsy 
NCAM expressing renal interstitial cells 
p value 
Absent Present  

















Serum creatinine [μmol/L]  146.64 ± 136.28 200.07 ± 239.45 0.244 
Creatinine clearance [ml/min]  77.56 ± 39.49 104.32 ± 70.19 0.199 
eGFR [ml/min/1.73m
2
]   73.80 ± 47.49 74.56 ± 47.21 0.952 
Urea [mmol/L]   10.61 ± 8.66 11.037 ± 8.17 0.838 
Glucose [mmol/L]   5.15 ± 1.11 4.76 ± 0.81 0.115 
Eritrocyturia  n (%) 
absent 15(44.1%) 19 (55.9%) 
0.585 
present 12 (37.5%) 20 (62.5%) 
Proteinuria [g/24h]   8.41 ± 9.45 3.97 ± 2.63 0.024* 
Red blood cells [×10
12
/L]   4.09 ± 0.66 4.09±0.76 0.999 
Hemoglobin [g/L]   122.85 ± 16.77 121.61 ± 25.01 0.852 
Hematocrit   0.35 ± 0.91 0.37 ±0.07 0.297 











Table 4.3.3. Clinical and laboratory parameters recorded at the time of last medical 
examination in patients with and without NCAM expressing renal interstitial cells. 
Clinical and laboratory parameters recorded at the 
time of last medical examination 
NCAM expressing renal interstitial cells 
p value 
Absent Present 
CKD stage  n (%) 
CKD 1 9 (45.0%) 11 (55.0%) 
0.601 
CKD 2 1 (14.3%) 6 (85.7%) 
CKD 3 1 (25.0%) 3 (75.0%) 
CKD 4 4 (100.0%) 0 (0.0%) 
CKD 5 2 (22.2%) 7 (77.8%) 
Serum creatinine [μmol/L]  183.95 ± 242.20 183.95 ± 242.20 0.560 
Creatinine clearance [ml/min]  86.75 ± 46.34 86.75 ± 46.34 0.334 
eGFR [ml/min/1.73m
2
] 74.59 ± 51.60 74.59 ± 51.60 0.744 
Urea [mmol/L] 
 
12.24 ± 11.64 12.00 ± 10.50 0.938 
Glucose [mmol/L] 5.27 ±2.24 5.27 ±2.24 0.175 
Eritrocyturia  n (%) 
absent 10 (34.5%) 19 (65.5%) 
0.547 
present 9 (42.9%) 12 (57.1%) 
Proteinuria [g/24h] 2.58 ± 2.36 2.58 ± 2.36 0.993 
Red blood cells [×10
12
/L]   3.43 ± 1.43 4.14 ±0.78 0.962 
Hemoglobin [g/L]   120.20 ± 17.1 123.71 ± 18.54 0.63 
Hematocrit   0.34 ± 0.05 0.39 ± 0.10 0.211 





Figure 4.3.1. Probability of preservation of kidney function depending on the 






Since it has been previously shown in animal models that NCAM interstitial detection could be 
transiently observed following hypoxic kidney injury (88), we felt encouraged to investigate 
NCAM relations to HIF molecules, as well as their relations to EPO productions. NCAM and 
HIF-2α were rarely co-expressed on the same cell, and expression pattern of HIF-2α in these 
cells included only cytoplasmic localization (Fig.4.3.2). However, NCAM expressing renal 
interstitial cells did not express EPO, as we already showed, but sometimes rare cells in the 
glomerular tuft exhibited NCAM/EPO co-localization (Fig.4.3.2).   
 
Figure 4.3.2. NCAM co-expression with HIF-2α in renal interstitial cell and NCAM/EPO 
co-expression in the cell of glomerular tuft. 
 
Furthermore, HIF-2α was found to be widely expressed in the nuclei both in interstitial cells and 
tubular epithelial cells, but strongly associated with some signs of chronic renal parenchymal 
damage, such as renal interstitial fibrosis (Fig.4.3.3.). However, HIF-1α was rarely detectable in 
the human kidney biopsy samples and was mainly found in almost normal interstitial 




Figure 4.3.3. HIF-2α nuclear expressions (green) in renal interstitial cell within widened 
and fibrotic interstitial compartment and the same expression pattern in tubular epithelial 





Figure 4.3.4. HIF-1α (green) nuclear expressions in renal interstitial cell could not be 
observed neither within cells of the widened and fibrotic interstitial compartment nor 
within atrophic tubular epithelial cells, whereas rare EPO producing cells (red) situated 






4.4.TGF-β down-stream effectors in kidney biopsy samples 
4.4.1. SMAD2 SMAD3 and SNAIL – immunohistochemistry 
Among 47 biopsy samples of patients presented with proteinuria (alone or as a part of nephrotic 
syndrome), SMAD3 was detected in all cases exhibiting constitutive expression in distal tubules 
and collecting ducts with cytoplasmic and membranous expression pattern (Fig.4.4.1.1.). 
Proximal tubular epithelial cells and atrophic tubuli did not express SMAD3, as shown on 




Fig 4.4.1.1. SMAD3 expression in kidney biopsies.  (A) Immunopositivity of collecting ducts 
in renal medulla; (B) Immunopositivity of distal tubules in renal cortex; (C) Abundant interstitial 
fibrosis and tubular atrophy with global glomerulosclerosis in patient with end-stage kidney 
disease, PAS ×400; (D) Immunopositivity of collecting ducts in renal cortex and the absence of 





Therefore, SMAD3 immunoreactivity was characteristic of morphologically preserved cortical 
and medullar distal tubules and collecting ducts and was not related to chronic renal parenchymal 
damages (interstitial fibrosis and tubular atrophy). On the other hand, SMAD2 protein was 
expressed in nuclei of many epithelial structures of nephron. This spectrum included distal 
tubules, collecting ducts and parietal cells of Bowman's capsule. Moreover, in contrast to 
SMAD3, SMAD2 was present diffusely in nuclei of all atrophic tubules surrounded by 
interstitial fibrosis (Figure 4.4.1.2.A), whereby morphologically preserved proximal tubules were 
devoid of SMAD2 immunoreactivity.  
SNAIL transcription factor had almost identical distribution and pattern of expressions as 
SMAD2. Thus, all atrophic tubules with SMAD2 presence in nuclei displayed also expression of 
SNAIL (Figure 4.4.1.2.B). Furthermore, we showed statistically significant correlation of 
SMAD2 and SNAIL expression in tubular epithelial cells with interstitial fibrosis (p<0.001) and 
tubular atrophy (p<0.001), as presented in Figure 4.4.1.3. Additionally, variable frequency of 
SNAIL expression was observed in glomerular podocytes. We have noticed that patients with 
neprhotic range proteinuria expressed SNAIL in podocytes (Figure 4.4.1.2.C), while in those 










Figure 4.4.1.3. SMAD2 and SNAIL expressions in kidney biopsy samples (A) 
Immunopositivity of atrophic tubules surrounded with interstitial fibrosis, SMAD2 ×400; (B) 
Immunopositivity of atrophic tubules surrounded with interstitial fibrosis,  SNAIL ×400; (C) 
SNAIL expression in podocytes in patient with nephrotic range proteinuria, ×400; (D) The 
absence of SNAIL expression in podocytes in patient with sub-nephrotic proteinuria value, ×400. 
 
Figure 4.4.1.3. Distribution of SMAD2 and SNAIL tubular nuclear expressions with regard 





4.4.2. SMAD2, SMAD3 and SNAIL - clinico-immunomorphological correlations  
It has been statistically confirmed that patients who expressed SMAD2 in nuclei of proximal 
tubule cells (i.e. all atrophic tubuli) had significantly higher urea and creatinine levels, as well as 
significantly reduced eGFR (Table 4.4.2.1). Furthermore, there were statistically significant 
more SMAD2 and SNAIL positive cases (with regard to nuclear tubular expression) with each 
increase in CKD stage, as shown in Table 4.4.2.1. 
Table 4.4.2.1. Clinical and laboratory parameters recorded at the time of biopsy in patients 
with and without SMAD2 and SNAIL expressing tubular epithelial cells. 
Clinical and laboratory parameters  
SMAD2 and SNAIL expressing tubular epithelial cells 
p value 
Absent Present  
Age (years) 
 
40.0±17.6 44.9±14.8 0.354 
CKD stage n (%) 
CKD1 9 (69.2%) 4 (30.8%) 
0.001* 
CKD2 3 (30.0%) 7 (70.0%) 
CKD3 2 (16.7%) 10 (83.3%) 
CKD4 0 (0.0%) 4 (100%) 
CKD5 0 (0.0%) 1 (100%) 





95.9±33.3 61.7±38.1 0.007* 
Urea [mmol/L] 
 
7.3±1.9 9.8±4.9 0.026* 
Glucose [mmol/L] 
 
5.0±0.6 4.9±0.9 0.795 
Proteinuria [g/24h] 
 
4.2±2.3 6.2±4.5 0.072 
SNAIL expression in podocytes was clinically followed with higher proteinuria values. The 
average level of proteinuria in patients with SNAIL expression in podocytes was 7,4±3,5 g/24h, 






4.4.3. Immunofluorescent detection of TWIST, activated form of SMAD proteins and 
SNAIL protein 
TWIST has been considered to be involved in EMT events and could be induced by TGF-β 
ligand. In the analyzed human kidney biopsy samples, TWIST was occasionally detected in 
proximal tubular epithelial cells (as labeled with N-cadherin) even in the absence of chronical 
tubulointerstitial damages (right panel on Fig.4.4.3.1.). However, normal proximal tubuli were 
usually labeled only with N-cadherin but not with TWIST (left panel on Fig.4.4.3.1.). 
Since immunohistochemistry gave useful hint for further investigations but provided 
immunolabeling with a lot of background staining, we further wanted to explore the presence of 
activated SMAD forms (phosphorylated) and to check SNAIL and TWIST expression using 
imunofluorescent labeling. Surprisingly, we found variable pSMAD2 and pSMAD3 
immunofluorescent staining among cases. Thus, pSMAD2 was expressed focally in tubular 
epithelial cells and sometimes was associated with MMP2 immunopositivity, as illustrated on 
Figure 4.3.3.1.A. The same pattern in tubular compartment was observed with pSMAD3 and 
MMP9 (Figure 4.3.3.1.B). However, pSMAD2, but not pSMAD3, was visible in renal interstitial 
cells closely packed between tubuli (Figure 4.3.3.1.C), as well as in glomerular tuft of the case 
with diabetic glomerolopathy (Figure 4.3.3.1.D). SNAIL was expressed exclusively in podocytes 
of patients with nephrotic range proteinuria and could not be detected in any other compartment 
by immunofluorescence (Figure 4.3.3.1E and F).  
 




Figure 4.4.3.2. pSMAD2, pSMAD3 and SNAIL immunofluorescent labeling with additional 
double staining with MMP2, MMP9 and α-SMA in human kidney biopsies. A) pSMAD2 
(green) and MMP2 (red); B) pSMAD3 (green) and MMP9 (red); C) pSMAD2 widespread 
interstitial expression in the case of diabetic nephropathy; D) pSMAD2 glomerular expression in 
the same case of diabetic nephropathy; E) SNAIL expression in glomerulus of patient clinically 
presented with nephrotic range proteinuria; F) Glomerular SNAIL (green) and interstitial α-SMA 
(red) expressions in patient clinically presented with nephrotic range proteinuria.  
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4.5.Gene expression levels - kidney biopsy samples of renal fibrosis 
It has been observed that NCAM-140 became higher expressed in advanced IRF stages, and 
FGFR1 has been shown similar trend, as shown on Fig. 4.5.1.  
 
Figure 4.5.1. NCAM-140 and FGFR1 mRNA expression levels among different IRF 
degrees. 
The most prominent changes within various stages of renal interstitial fibrosis were detected in 
mRNA expression levels of ITGA5 and ITGB1. Fig. 4.5.2 illustartes extremely high ITGA5 
expression in the most severe IRF stage. 
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FSP1 was the most prominent in the earliest stage of fibrosis (IRF-1), while α-SMA mRNA was 
the highest in the most advanced stage (IRF-3), as shoen on the Fig.4.5.3. 
 
Figure 4.5.3. FSP1 and α-SMA mRNA expression levels among different IRF degrees. 
RUNX1, RUNX1T1 and PRMT1 showed increased expressions in higher IRF stages. (Fig.4.5.4) 
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Considering increased expressions of aforementioned genes with each increase in severity of 
renal interstitial fibrosis, regardless of the underlying kidney diseases, we further explored their 
correlations with RUNX1 transcription factor since RUNX1 is one of known transcriptional 
inducers of NCAM expression (89). Considering also that RUNX1 activity can be stimulated by 
PRMT1 induced methylation (90) and suppressed by RUNX1T1 (91), we have been searched 





















4.6.The effects of TGF-β on kidney tubular epithelial cells (HK-2 cells) and    
modulation of these effects by FGFR inhibitor  
4.6.1.  Time-dependant morphological changes of HK-2 cells 
Based on the cell morphology, clear influence of TGF-β1 was detected 72h after stimulation. As 
shown in the Fig.4.6.1.1, cells were spindle-shaped and acquired fibroblast-like morphology. 
PD173074 completely prevented such morphological changes under the TGF-β1 influence, 
leading to preservation of normal epithelial shape of HK-2 cells. 
 
Figure 4.6.1.1. Time dependant morphological changes induced by TGF-β1 and modulated 




4.6.2. Migration sctratch assay 
 
 
Figure 4.6.2.1. Pictures captured at the time of treatment and scratch (0 day) and next 





Figure 4.6.2.2. Pictures captured on the second and third experimental days. 
As shown in the Fig.4.6.2.1 and 4.6.2.2., TGF-β1 treated cells migrated faster, and PD173074 
suppressed TGF-β1 induced potential of enhanced cell migration. 
Using scratch assay analysis, TGF-β1 treated cells migrated faster than control HK-2 cells, 
PD173074 treated, as well as TGF-β1+PD173074 treated cells. Thus, 24h after TGF-β1 
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stimulation, around 55% of scratch distance was visible, whereby in three other groups almost 
90% of initial scratch distance could be observed (Fig.4.6.2.3.). The same cell migration patterns 
were detected during the next two experimental days. Illustrations in the Fig.4.6.2.3 show clear 
difference in the migration capacity of cells treated with TGF-β1 compared to the cells 
stimulated with TGF-β1 in addition to PD173074 within three days. 
 
 








4.6.3. Gene expression analysis 
Initially, HK-2 cells were tested for the relative mRNA expression levels of NCAM (three 
isoforms: NCAM-120, NCAM-140, NCAM-180) and FGFR1 within control and TGF-β1 
(10ng/μl) treated group. qRT-PCR analysis revealed over-expression picks of both NCAMs and 
FGFR1 24h after TGF-β1 stimulation (Fig. 4.6.3.1 A), whereby morphological difference was 
not observed among these two group using light microscopy (Fig. 4.6.3.1 C). 
 
Figure 4.6.3.1. Time-dependant morphological and molecular changes upon TGF-β1 
stimulation of proximal tubular epithelial cells (HK2-cells). A) relative mRNA expression 
levels of NCAM isoforms and FGFR1 at 5 different time points (6h, 12h, 24h, 48h, 72h) after 
TGF-β1 treatment; B) relative mRNA expression levels of genes known to be affected during 
TGF-β1 stimulation measured 24h and 48h after TGF-β1 treatment of HK2-cells; C) cell 
morphology observed at three time points (24h, 48h, 72h) optico-microscopically in control 
group, as well as in groups treated with TGF-β1 alone and in addition to PD173074. 
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However, 48h upon TGF-β1 administration HK-2 cells started to change their phenotype 
acquiring somewhat spindle shape appearance, but still many of them resemble normal epithelial 
morphology (Fig. 4.6.3.1 C). At that time point, rapid decrement of NCAMs and FGFR1 mRNA 
levels was observed (Fig. 4.6.3.1 A). Furthermore, genes known to be affected in TGF-β1 
induced fibrosis were highly over-expressed 48h after stimulation, whilst their expressions were 
low the day before (24h after TGF-β1) as illustrated in Fig. 4.6.3.1 B. Since it seemed that over-
expression picks of NCAMs and FGFR1 were the earliest changes observed upon TGF-β1 
stimulation, and appreciating rapid decline of their mRNA levels even next day that were 
followed by increased expression of SLUG, SNAIL, TWIST, MMP2, MMP9, FSP-1 and α-
SMA, we hypothesized that at least FGFR1 could have an important role in the initiation of renal 
fibrosis in vitro. Thus, we further wanted to explore effects of FGFR1 inhibitor (PD173074) on 
TGF-β1 induced fibrosis, following cell morphology, cell migration, gene expressions and 
relevant protein expressions and localizations. 
Since the picks of genes up-regulations upon TGF-β1 stimulation were detected 48h after such 
treatment, we further followed gene expression levels under the impact of both PD173074 and 
TGF-β1 in order to clarify ability of PD173074 to modulate aforementioned transcriptional 
events.  
SLUG, SNAIL and TWIST 
Thus, 48h after TGF-β1 and PD173074 stimulation SLUG, SNAIL and TWIST were expressed 
at significantly lower levels compared to their expression under the influence of TGF-β1 alone 
(Fig. 4.6.3.2 A), achieving the levels similar to those observed in control HK-2 cells. At 72h 
SLUG mRNA (Fig. 4.6.3.2 B) was lower than 48h after experimental procedure. Although 
PD173074 suppressed SLUG up-regulation, the difference was not significant (Fig. 4.6.3.2 B). 
However, SNAIL remained up-regulated 72h after TGF-β1 stimulation, but unfortunately 
PD173074 could not significantly resist powerful TGF-β1 influence (Fig. 4.6.3.2 B). 
Furthermore, TWIST reached over-expression pick 72h upon TGF-β1 treatment, whereby such 




FSP-1 and α-SMA  
Both FSP-1 and α-SMA are considered as key contributors to tissue fibrosis. Consequently, it 
was not surprising that their relative mRNA expression levels were highly over-expressed in in 
vitro model of TGF-β1 induced renal fibrosis (Fig. 4.6.3.2 C and D). However, PD173074 
successfully suppressed extremely extensive up-regulation of either FSP-1 or α-SMA, as shown 
in Fig. 4.6.3.2 C and D. 
 
 
Figure 4.6.3.2. Modulation of gene expressions by PD173074 in TGF-β1 stimulated HK-2 




E-cadherin and N-cadherin  
It has been shown that switch of cadherins appeared 48h after TGF-β1 application, persisting 
also the next day (Fig.4.6.3.3). Thus, a remarkable molecular trait of TGF-β1 influence on HK-2 
cells was E-cadherin down-regulation followed by up-regulation of N-cadherin. The effect of 
PD173074 on modulation of cadherin expressions was not too strong at the beginning (48h), but 
became striking on the third day (72h). Indeed, the third experimental day was accompanied by 
almost complete restoration of cadherin expression. 
  
Figure 4.6.3.3. Modulation of gene expressions by PD173074 in TGF-β1 stimulated HK-2 
cells: E-cadherin and N-cadherin relative mRNA expression levels. 
 
MMP2 and MMP9 
MMP2 responded stronger than MMP9 during TGF-β1 stimulation (Fig. 4.6.3.4). PD173074 
succeeded to prevent high over-expressions of both MMPs, but still MMP2 remained up-





Figure 4.6.3.4. Modulation of gene expressions by PD173074 in TGF-β1 stimulated HK-2 
cells: MMP2 and MMP9 relative mRNA expression levels. 
 
Integrins (ITGA5 and ITGB1) 
In response to TGF-β1 stimulation, HK-2 cells upregulated expressions of both ITGA5 and 
ITGB1, whereby ITGB1 mRNA levels were slightly higher compared to ITGA5.   Statistically 
significant down-regulation of both ITGA5 and ITGB1 was observed upon PD173074 treatment 
in the cells stimulated with TGF-β1 (Fig. 4.6.3.5). Although ITGA5 was still overexpressed 48h 
after treatment, an observed downregulation was significant, and it became confident next 
experimental day (72h).  
  
Figure 4.6.3.5. Modulation of gene expressions by PD173074 in TGF-β1 stimulated HK-2 
cells: ITGA5 and ITGB1 relative mRNA expression levels. 
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FGFR1 and FGFR2 isoforms (IIIb and IIIc) 
qRT-PCR primers for FGFR1 and FGFR2 IIIb and IIIc isoforms were not good enough to get 
strong conclusions. As illustrated below (Fig. 4.6.3.6), on the amplification plots GAPDH was 
excellent, while FGFR1 IIIb and FGFR2 IIIc were not satisfying but not so bad. Moreover, 

















Thus, we presented on the Fig. 4.6.3.7 total FGFR1 and FGFR2, as well as mRNA levels of 
FGFR1 IIIb and FGFR2 IIIc isoforms. Despite over-expression of total FGFR1 and FGFR2, both 
FGFR1 IIIb and FGFR2 IIIc isoforms were downregulated upon TGF-β stimulation and were 
restored after PD173074 administration (Fig. 4.6.3.7).  
  
Figure 4.6.3.7. Modulation of gene expressions by PD173074 in TGF-β1 stimulated HK-2 
cells: total FGFR1 and FGFR1 IIIb isoform and total FGFR2 and FGFR2 IIIc isoform - 
relative mRNA expression levels 48h after treatment. 
 
4.6.4. Protein expression detected by double immunofluorecent labeling 
Since previous results (with regard to cell morphology, their migration capacity and gene 
expressions estimated by qRT-PCR) suggested potential of FGFR inhibitor (PD173074) to 
suppress TGF-β1 effects on HK-2 cells, we further wanted to evaluate presence and localization 
of TGF-β1 down-stream effectors, such as SMAD proteins, as well as transcription factors up-
regulated in response to TGF-β1/SMAD signaling (SNAIL and TWIST). Considering α-SMA 
and N-cadherin up-regulation upon TGF-β1 treatment and their decrement after PD173074 
application in TGF-β1 treated HK-2 cells, we performed immunolabeling using these two 
antibodies in the experimental groups. Moreover, vimentin as an intermediate filament protein 
characteristic for mesenchymal cells, and Ki-67 as marker of proliferation were also explored by 
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PD173074 prevented pSMAD2 and pSMAD3 appearance in the nuclei 
SMAD2 and SMAD3 proteins became phosphorylated upon TGF-β1 and were detected in the 
nuclear compartment as pSMAD2 and pSMAD3 either 48 (Fig. 4.6.4.1) or 72h (Fig. 4.6.4.2) 
after stimulation (panels on the left side). 
 
Figure 4.6.4.1. Double immunofluorescent labeling: pSMAD2/Vimentin and pSMAD3/Ki-
67 – 48h after treatment. 
These green fluorescent dots representing aforementioned pSMAD proteins could not be visible 
in the TGF-β1+PD173074 treated cells (Fig. 4.6.4.1 and Fig. 4.6.4.2, panels on the right side), 
suggesting that PD173074 (known as FGFR inhibitor) suppressed TGF-β1 signaling through 





Figure 4.6.4.2. Double immunofluorescent labeling: pSMAD2/Vimentin and pSMAD3/Ki-
67 – 72h after treatment. 
Since PD173074 acts as small ATP competitive inhibitor of tyrosine/kinase receptors it was not 
clear why serine/threonine dependant phosphorylation of SMAD proteins was affected by 
administration of PD173074. Thus, we decided to look at even earlier time point and performed 
immunolabeling 24h after stimulation with TGF-β1 alone and with TGF-β1+PD173074. 
Surprisingly, pSMAD3 was detected in the cytosol, but not in the nuclei, in both experimental 
groups (Fig. 4.6.4.3), indirectly implicating that PD173074 did not cross-react with 
serine/threonine dependent SMAD phosphorylation. Possible explanation for later disappearance 
of pSMAD3 from the cells treated with TGF-β1+PD173074 could be that prolonged effect of 





Figure 4.6.4.3. Immunofluorescent labeling of pSMAD3 in HK-2 cells 24h after treatment 
with TGF-β1 alone and in addition to PD173074. 
 
PD173074 preserved vimentin expression and did not affect cell proliferation capacity 
Although vimentin is known as intermediate filament protein of mesenchymal cells, it is 
constitutively expressed in normal human proximal epithelial cells. As shown on Fig. 4.6.4.1 and 
Fig. 4.6.4.2, vimentin (red) is expressed upon exposure to TGF-β1 (diffusely), as well as upon 
additional stimulation with PD173074 (perinuclearly).  
Based on immunofluorescent staining, nuclear detection of Ki-67 (red) was observed in each 
cell, thus there was no influence of PD173074 on the cell proliferation (Fig. 4.6.4.1 and Fig. 
4.6.4.2), although migration capacity was reduced (Fig. 4.6.2.3). 
Influence of PD73074 on the presence and localization of SNAIL and TWIST 
TGF-β1 stimulation caused widespread SNAIL protein expression (Fig. 4.6.4.4 and Fig. 4.6.4.5), 
beside its effects on significant transcriptional up-regulation of SNAL mRNA (Fig. 4.6.3.2 A and 






Figure 4.6.4.4. Double immunofluorescent labeling: SNAIL/α-SMA and TWIST/N-cadh – 
48h after treatment. 
These findings were confirmed the next day (72h), whereby an immunofluorescent signal (green) 
became even stronger in the nuclear compartment (Fig. 4.6.4.5). Treatment with PD173074 
succeeded to prevent SNAIL protein appearance either in cytoplasm or nuclei during 48h of 
experimental procedures (Fig. 4.6.4.4) and that was in accordance with highly down-regulated 
SNAIL mRNA expression as shown on Fig. 4.6.3.2 A.  However, 72h upon treatment together 
with TGF-β1 and PD173074, SNAIL became slightly detectable in nuclei of few HK-2 cells 
(Fig. 4.6.4.5) but still more than significantly less compared to TGF-β1 treated group. 
TWIST was significantly over-expressed in TGF-β1 treated group both on mRNA (Fig. 4.6.3.2) 
and protein level (Fig.4.6.4.4 and Fig. 4.6.4.5). Although PD173074 reduced TWIST mRNA 
level (Fig. 4.6.3.2, panels A and B), TWIST protein was still visible in the cells. However, it is 
very important to notice that at 48h TWIST was mainly detected in cytoplasm, whereby its 
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protein expression was also detected in nuclei of some HK-2 cells stimulated with PD173074 
and TGF-β1. 
 
Figure 4.6.4.5. Double immunofluorescent labeling: SNAIL/α-SMA and TWIST/N-cadh – 











PD173074 completely prevented α-SMA protein expression upon TGF-β1 stimulation, but 
did not influence N-cadherin 
α-SMA, as a crucial protein expressed upon TGF-β1 stimulation, was observed in cytoplasm of 
HK-2 cells both 48h and 72h after  TGF-β1 treatment (Fig. 4.6.4.4 and 4.6.4.5). This phenotype 
was not detected in the group stimulated with PD173074 and TGF-β1 together, since α-SMA 
was not visible on the protein level in any cell (Fig. 4.6.4.4 and 4.6.4.5). These results obtained 
by immunofluorescent labeling were in accordance with qRT-PCR data (Fig. 4.6.3.2 C and D).  
Despite significant changes of N-cadherin mRNA observed among control, TGF-β1 and TGF-
β1-PD173074 treated groups of HK-2 cells (Fig.4.6.3.3), immunolabeling discovered the 
presence of N-cadherin (cell surface red immunofluorecent signal) in all groups (Fig. 4.6.4.4 and 




5. DISCUSSION  
Progression of chronic kidney disease (CKD) remains an unsolved problem in clinical 
nephrology since approaches to reverse or repair chronic renal injury are not yet available (92). 
Independent of the underlying disease, loss of functional kidney parenchyma and tubulo-
interstitial fibrogenesis are commonly observed when kidney injury progresses towards CKD (9). 
In this regard, epithelial-to-mesenchymal transition (EMT) in tubular epithelial cells (TECs) and 
consecutive G2/M arrest have been shown to determine maladaptive kidney repair in response to 
injury, ultimately associated with renal fibrogenesis and progression into CKD (40, 93, 94). 
Persistent effort to modulate CKD progression has led scientists to better understand molecular 
mechanisms driving renal fibrosis (95). TGF-β1 is considered as a key mediator of intrarenal 
EMT program and renal fibrosis (10, 96, 97). Preclinical studies found many effective strategies 
to attenuate EMT program in rodents (11-13), but only a few of them are applicable in humans 
(10). Moreover, some of the proposed therapy strategies were efficient to reduce fibrosis, but 
unfortunately it stimulated inflammation (98). Thus, further investigations to develop new 
strategies to modulate EMT program should be focused on down-stream effectors of TGF-β1 
signaling pathway. 
NCAM and FGFR signaling during EMT program have already been described and it has been 
noticed that both molecules are fundamental for EMT program in vitro (99-102; 24-26, 14). 
Moreover, their up-regulations in response to TGF- β have been also previously detected (103-
107). Thus, it encouraged us to investigate aforementioned molecules in human kidneys and to 
evaluate their significance in fibrotic response within the renal interstitial compartment.  
NCAM and renal fibrosis: its isoforms and possible transcriptional regulation 
Here we presented that NCAM cells were really scarce in the normal interstitial compartment of 
the kidney and were almost exclusively increased at the beginning of renal interstitial fibrosis, 
independently of the underling diagnosis. Looking deeper at the molecular background, NCAM-
140 isoform appeared to be a hallmark of these NCAM+ cells in incipient renal fibrosis since it 
was specifically over-expressed in those kidneys compared to NCAM+ cells found in normal 
interstitium. Furthermore, it has been observed that NCAM-140 isoform is also over-expressed 
focally in the cardiomiocytes as reaction to local scar formation in ischemic cardiomyopathy (89, 
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108). Since molecular characterization of NCAM expressing renal interstitial cells revealed their 
heterogeneity, we enrolled series of experimental procedure in order to see whether these cells 
could further contribute to progression of renal fibrosis or they could serve as counteracting 
mechanisms preventing/ameliorating such disease progression. 
Taking into account that NCAM is widely expressed during embryonic kidney development in 
metanephric mesenchyme and its derivates and progressively disappears during maturation of 
structures which further forms nephron unit in the kidney through the process of mesenchymal-
to-epithelial transformation (MET) (86, 109), we thought that rare interstitial NCAM expressing 
cells in mature adult kidney could represent population of resident metanephric mesenchymal 
cells with self-renewing and stem like properties. However, it was hard to perceive possible 
origin of increased NCAM+ cell population within the diseases kidneys with early interstitial 
fibrosis. Thus, there were several possible explanations for this phenomenon. I might be that an 
increased number of NCAM+ renal interstitial cells arise from enhanced proliferation of resident 
NCAM+ cells, however the question is whether these resident cell have such high proliferation 
capacity to fill abundantly the interstitial compartment as observed in early stages of renal 
fibrosis. The second possibility is that NCAM molecule appears on the surface of some kind of 
fibroblasts, such heterogeneous within the fibrotic interstitium, during the course of renal 
fibrosis. It could be supported by the presence of HE4 protein in some NCAM+ cells, since HE4 
is newly labeled as marker of activated fibroblasts (28). However, the most interesting question 
for us was whether an increased number of NCAM+ interstitial cells could represent transient 
phenotype of tubular epithelial cells undergoing EMT and serve as an evidence of in vivo EMT 
process within the kidney following tubular injury. This question looks the most exciting, but 
this answer is the most difficult to be given. Although EMT is widely investigated by numerous 
researchers in in vitro studies (17), there is a lacking of evidence that such process contribute to 
fibrogenesis in vivo. This hypothesis made controversies and polemics in science (110, 111).  
Despite these controversial opinions with regard to existence of EMT driving fibrosis in vivo 
(110, 111), in vitro studies could be helpful in determination of molecular function and could 




Here we used an established in vitro model of EMT induced renal fibrosis, applying TGF-β1 as a 
major trigger of EMT program in cultured proximal tubular epithelial cells of the kidney (HK-2 
cells). We followed various EMT events at several time points during 96 hours and carefully 
monitored changes, including gene expression levels. Thus, the robust induction of all three 
NCAM isoforms was observed with the highest mRNA levels 24h after EMT program 
stimulation. In accordance with our results are the findings arisen from the study of Lehembre et 
al (14). Moreover, it has been also previously reported that TGF-β is involved in modulation of 
NCAM expression, inducing up-regulation of all three major NCAM isoforms, mainly NCAM-
140, but also in a lesser extent two others (NCAM-120 and NCAM-180) (103-105). 
TGF-β, the major activator of EMT program, seems to act by stimulating the transcriptional 
activity of the NCAM gene (104). There are several transcription factors with potential binding 
site to NCAM promoter region (NF-kappa B, PAX, HOX, RUNX1). However, it seemed that 
RUNX1 could be directly involved in the stimulation of aberrant NCAM expression, since other 
known transcription factors are usually constitutively expressed, while RUNX1 follows the trend 
of NCAM-140 up-regulation (89). Thus we proceeded to the next investigation step and 
performed kidney tissue lysates of the 16 patients suffered from various glomerulonephritides 
and glomerulopathies whose biopsies revealed different degrees of interstitial fibrosis. Here we 
examined expression of NCAM-140 isoform, as well its potential transcription factor RUNX1. 
qRT-PCR analysis discovered increasing relative mRNA expressions of both NCAM-140 and 
RUNX1 with increasing IRF stages, implicating that NCAM-140 up-regulation in severely 
affected kidneys with IRF can be result of over-expression of RUNX1 gene. Furthermore, 
PRMT1 as a known epigenetic positive regulator of RUNX1 is also highly expressed in 
advanced IRF stages following the same dynamics of both NCAM-140 and RUNX1 mRNA 
expressions. Unfortunately, these observations with regard to NCAM-140 expression levels are 
not in accordance with the finding of immunolabeling using NCAM antibody, since in 
morphologically NCAM+ cells were most numerous in the less severe IRF in the kidney biopsy 
samples. In order to try to explain this inconsistency between NCAM mRNA levels and protein 
detection among various IRF stages, afterward one more gene is explored on the mRNA level – 
RUNX1T1 as a putative repressor of RUNX1. Surprisingly we found nearly 400 times fold 
increase in RUNX1T1 in the most advanced IRF stage. Despite obvious increase in PRMT1 (159 
times fold increase) and RUNX1 (79 times fold increase), it is very likely that huge RUNX1T1 
85 
 
over-expression overcomes the possible effects of NCAM-140 inducers. Although RUNX1T1 
has not been well studied alone yet, its function is usually considered through the roles of 
RUNX1/RUNX1T1fusion oncoprotein. Nevertheless, these findings have to be further explored 
and it is possible that distinct explanations for currently acquired data in our study would be 
available.  
NCAM signaling pathways 
NCAM is not a simple adhesion molecule, but it is rather involved in signaling cascades essential 
for many physiological processes and could be also aberrantly activated during variable 
pathological conditions (89, 101, 108). 
Since NCAM was apparently up-regulated early upon response to TGF-β1 and considering its 
potential signaling not only by NCAM-NCAM homophilic bindings but also its signaling 
through the activation of FGFR signaling pathway, we tried to find any potential relationship 
between NCAM and FGFR during fibrotic response in kidney and their association with EMT 
program. Indeed, here we present that both NCAM and FGFR1 are rapidly over-expressed after 
EMT program induction, implicating their role in the initiation of EMT in proximal tubular 
epithelial cells (TECs). Although all three NCAM isoforms were up-regulated during EMT 
program in TECs, the most prominent was the expression of NCAM-140. Furthermore, applying 
qRT-PCR we also revealed significant increase of NCAM-140 and FGFR1 mRNAs with 
progression of renal fibrosis in human biopsy samples. Lehembre et al. also showed that upon 
TGF-β EMT induction, NCAM starts to be more expressed, specifically its 140kDa isofrom (14). 
These findings were the triggers for subsequent investigation steps stimulating us to further 
clarify their relation to other molecules known to be involved during NCAM and FGFR 
signaling. Beside heterophilic NCAM interaction with FGFR (cell-cell interaction), it is also 
involved in cell-matrix interactions through the interactions with integrins. Thus, ITGB1 
(integrin β1) was found to be important for neuroblastoma cell migration through the interplay 
with NCAM-140 (112). Furthermore, it has been illustrated that this process depends on 
MAPK/ERK activation. Since ERK is the point of convergence of NCAM-NCAM and NCAM-
FGFR pathways, the investigator applied MAPK and FGFR (50 nM PD173074) inhibitors. They 
found that NCAM/integrin β1dependant cell migration was FGFR independent, although 
requires MAPK/ERK signaling cascade that might be induced through the other mechanisms 
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including NCAM-NCAM interactions (112). However, in our experiments it has been shown 
enhanced HK-2 cell migration toward TGF-β1 could be significantly suppressed by PD173074, 
thus leading us to conclude that FGFR signaling play an important role in cell migration during 
EMT program induced in HK-2 cells. Since in the absence of FGF ligands, a highly over-
expressed FGFR1 could be stimulated only by interaction with NCAM (up-regulated in the same 
manner, after TGF-β1 induction), we concluded that forced migration of HK2-cells undergoing 
TGF-β1 induced EMT is highly dependent on NCAM/FGFR1 signaling pathway. In parallel, 
performed qRT-PCR analysis shows also significant decrease of ITGB1 upon FGFR signaling 
blockade. In human biopsy samples, ITGB1 follows the same trend of expression as NCAM-140 
and was highly expressed in the most advance fibrosis stage. Beside, stimulation of cell 
migration undergoing EMT, integrity of NCAM/FGFR1 signaling appeared to be important for 
the induction and maintenance of mesenchymal morphological and molecular traits, and will be 
further discussed. Since β1 usually makes a complex with α5 subunit of integrin (113), and 
considering an involvement of α5 integrin in fibroblast activation and contribution to progression 
of renal fibrosis (5), we became encouraged to assess α5 integrin mRNA expression during EMT 
in vitro and renal fibrosis in human biopsy samples. It has been found here that ITGA5 mRNA 
expression levels increase during EMT program and could be sufficiently down-regulated by 
inhibition of NCAM/FGFR signaling. Moreover, in human kidneys, mRNA levels of ITGA5 
correlate with the degree of interstitial fibrosis. Thus, in the interstitium widely affected with 
fibrosis the levels of ITGA5 were the highest. Integrin α5 is already found to be significantly up-
regulated in response to TGF-β in murine tubular epithelial cells (114). Since α5 subunit defines 
binding site to ECM components of α5β1 integrin, it has been proposed that it has high affinity 
to fibronectin (15, 113). 
Moreover, several studies also suggested that both NCAM and FGFR are fundamental for EMT 
in vitro. However, it has been also indicated that alternative splicing of FGFRs’ Ig3 (D3) domain 
generates IIIb and IIIc isoforms influencing distinct affinity of FGFRs to their FGF and other 
ligands (83). NCAM specifically binds by its second FNIII domain to Ig2 and Ig3 FGFRs 
domains (24, 26). However, since FGFR isoforms differ in Ig3 domain, researchers further found 
the NCAM interacts with IIIc FGFR isoforms (24, 26, 115). 
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FGFRs IIIb isoforms are characteristically found in epithelial cells, whereas IIIc isoforms are 
known to be expressed by mesenchymal cells and during carcinogenesis, leading to disease 
progression (116, 117).  Thus, it was reasonable to further consider expressions of specific FGFR 
isoforms during EMT program. It has been noticed TGF-β1 induced switches from IIIb to IIIc 
isoform (116). However, they found that FGFR2 IIIb isoform is characteristically expressed by 
NMuMG cells, and EMT induced acquisition of FGFR1 IIIc isoform. It indicates that not only 
alternative splicing changes during EMT, but also FGF receptor type could be affected. 
Accordingly, in our study we have tried to explore the influence of TGF-β1 on the expression 
levels of alternatively spliced FGFR1 and FGFR2 isoforms (IIIb and IIIc). However, we have not 
been able to make strong conclusions because the lacking of evidence for mRNA expressions of 
FGFR1 IIIc and FGFR2 IIIb isoforms, but we suggested that both FGFR1 IIIb and FGFR2 IIIc 
isoforms could be down-regulated in response to the EMT program induction. Nevertheless, 
since we observed over-expression of both total FGFR1 and FGFR2 mRNAs, it could be 
indirectly concluded that these over-expressions resulted from FGFR1 IIIc and FGFR2 IIIb 
isoforms up-regulation (since the second isoform of both FGFRs were down-regulated). 
Moreover, these changes were almost completely restored by inhibition of NCAM/FGFR 
signaling (by PD173074), implicating that specific FGFR isoforms are required for the 
interaction with NCAM and consecutive signaling during EMT of HK-2 cells. 
Molecular background of renal fibrosis in human kidneys: an involvement of 
TGF-β signaling pathway 
TGF-β1 has been widely investigated in many in vitro and in vivo models of organ fibrosis, 
including those in kidneys. However, the morphological evidence of the existence and 
contribution of this signaling pathway to human kidney fibrosis in vivo have not been completely 
clarified yet. Hence, here we were able to present that major down-stream signaling effectors of 
TGF-β1 are expressed in many epithelial structures in human kidneys either morphologically 
preserved or damaged. An abundant constitutive expression of pSMAD2/3 is already found in 
distal tubules and collecting ducts in human kidneys (118). However, they found co-localization 
of pSMAD2/3 and SNAIL with vimentin in tubules exhibiting EMT like features in human 
kidney transplants (118). Beside constitutive expressions of SMADs and SNAIL, our study 
revealed similar expression patterns of both SMAD2 and SNAIL as found in kidney grafts, and 
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they were significantly related to chronic renal parenchymal damages (tubular atrophy and 
interstitial fibrosis) influencing excretory renal functions with impaired response and leading to 
acquisition of more advanced CKD stages. It has been also shown that SNAIL is not simply 
related to morphological EMT features in kidney transplants (fibrosis), but was found to be 
significantly related to graft dysfunction (low eGFR levels) (118). Our study also revealed that 
activated SMADs (pSMAD2/SMAD3) are expressed in lesser extent than non-phosphorylated 
SMADs. Indeed, we did not find constitutive expression of pSMAD2/SMAD3 in human kidneys 
(by immunofluorescent labeling), but rather observed them in epithelial cells of some tubuli 
within the core biopsy. These tubuli also expressed MMP2 and MMP9, implicating an early 
disturbance that would probably lead to further tubular damage involving degradation of tubular 
basement membrane and providing access of transforming epithelial cells to the interstitial 
compartment, suggesting their potential to contribute fibrogenesis (an active process of ECM 
remodeling/production). An induction of MMP2 and MMP9 has been already found in epithelial 
cells as reaction to FGF-2 stimuli (119). 
SNAIL shares the same pattern of expression as SMAD2 in human kidney tubulointerstitial 
compartment, but also has an additional involvement in glomerular damage. Indeed, in parallel 
with affection of excretory function of the human kidney, SNAIL also contributes to impaired 
podocyte function. Thus, SNAIL expression by podocytes leads to appearance of nephrotic range 
proteinuria values. These findings did not surprise us since it has been previously shown that in 
nephrotic rats Snail is highly expressed in podocytes either on protein or in mRNA levels (120). 
The underling mechanism considers Snail induced repression of nephrin synthesis, as one of the 
important protein constituent of slit-diaphragm between glomerular podocytes. Additionally, 
there are evidences that also high glucose levels in mice are able to induce podocytes’ Snail 
over-expression, subsequently leading to down-regulation of both nephrin and podocin (121).  
However, both studies found that Wnt/β-Catenin pathway act up-stream of Snail induction in 
podocytes (120, 121), although is known that SNAIL can be induced by TGF-β as well (122). 
Induction of Snail is sufficient to induce renal fibrosis in animals, and high mRNA SNAIL levels 
are found in fibrotic human kidneys (123, 124). For the first time here we detected 
morphological evidence of the SNAIL involvement in chronic tubulointerstitial damages and 
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approved that aberrant SNAIL expression by podocytes could be responsible for nephrotic range 
proteinuria in patients.  
Our results that came from experimental induction of EMT program in tubular epithelial cells of 
the human kidney and that were confirmed in human biopsy samples suggested an involvement 
of both NCAM and FGFR in initiation step of renal fibrosis. In the same setting, other molecules 
that are known to be affected in fibrotic response were also examined. Thus, undoubtedly we 
found significant increase in mRNA levels of ITGA5 (encoding integrin α5) and ITGB1 
(encoding integrin β1) both after EMT program induction in vitro and in the whole human 
kidney tissue lysates. By increased severity of renal interstitial fibrosis, a gradual increment of 
both integrins’ mRNA was observed. α5β1 integrin is known marker of in vitro EMT (4), and is 
also previously detected in fibrotic kidneys (5, 85). α5β1 integrin cooperates in cell adhesion, 
proliferation and differentiation and plays a role in extracellular matrix assembly. When 
expressed by fibroblasts, α5β1 integrin promotes acquisition of a myofibroblastic phenotype with 
typical α-SMA expression pattern (5, 15, 14; 112). In EMT model, it has been shown that α5 
integrin knock-down results in attenuation of α-SMA (induced by TGF-β) but does not affect 
cells morphology (114), suggesting that α5 integrin could be involved in fibroblast activation. It 
has been shown that TWIST, acts up-stream of the α5 integrin induction during EMT program 
(125).  
Interstitial fibrosis and tubular atrophy are morphological hallmarks of CKD. The degree of 
affected tubulointerstitial compartment directly influences kidney function and serves as 
prognostic marker for renal failure. Fibroblasts are thought to be the main effectors cells in renal 
fibrogenesis. They reside within kidney cortex, as well as in perivascular area. However, 
fibroblasts do not have unique molecular traits but rather represent highly heterogeneous 
population situated within fibrotic area. Their activation leads to excessive production of ECM 
components. During activation some of these fibroblasts start to express α-SMA, a prototypic 
characteristic for myofibroblast. Some other fibroblasts could express FSP-1 and they are 
considered to be important in early phase of fibrogenesis (119, 126). FSP-1 is a cytoskeletal 
protein that belongs to calmodulin-S100-troponin C superfamily of intracellular calcium binding 
proteins, and is known to be expressed by mesenchymal cells influencing cell motility (127). 
FSP-1 stimulates fibronectin and collagen production. Numerous experimental procedures 
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demonstrated an induction of α-SMA and FSP-1 towards TGF-β1 stimulation. Our findings 
revealed up-regulation of both α-SMA and FSP-1 in human kidney samples with various degree 
of renal interstitial fibrosis. However, the highest over-expression of FSP-1 was found in early 
fibrosis stage (IRF-1), whereas α-SMA showed the highest relative mRNA level in the most 
severe fibrosis stage (IRF-3).          
Modulation of NCAM/FGFR signaling – relevance for renal fibrosis and 
implication for therapy 
NCAM induced FGFR signaling has been widely studied, mainly in neural tissues and cancer 
cells (14, 24-27, 99, 100, 115). However, there is a lacking of evidence for the contribution of 
their interplay to fibrogenesis, although several studies confirmed that both molecules can be 
separately involved such process (88, 106, 128). Thus, FGFR is widely studied in many fields of 
research, including fibrosis. Nevertheless, according to available data and our knowledge, 
involvement of NCAM expressing cells in renal fibrosis is only considered by our research group 
and also by Vansthertem and co-workers (85, 88, 129). Thus, for the first time, here we present a 
functional significance of NCAM and FGFR co-operation in the induction of renal fibrosis, 
mediated by TGF-β1. 
Hence, based on the previously discussed results from the beginning of our research we further 
suspected that modulation of NCAM/FGFR1 signaling can suppress EMT of human tubular 
epithelial cells (TECs), currently used as an established in vitro model of renal fibrosis and a 
good starting point for experiments that can be able to clarify molecular pathway underling such 
process. 
Firstly, we observed that morphologically TECs do not develop mesenchymal traits (spindle 
shape morphology) when treated with FGFR inhibitor (PD173074), despite an influence of TGF-
β1. This observation implicates an important role of NCAM/FGFR signaling in acquisition of 
mesenchymal characteristic of epithelial cells. Thus, we decided to explore important molecules 
that influence cell morphology such as intermediate filaments (vimentin and α-SMA - 
characteristic for mesenchymal cells and activated fibroblasts) and those involved in tight-
junction formation (E-cadherin and N-cadherin) (130-132). 
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However, HK-2 cells (human proximal tubular epithelial cells) share many features characteristic 
for the majority of epithelial cells, but also exhibit many differences, especially with regard to 
expression of vimentin, E-cadherin and N-cadherin. 
Vimentin 
Normal HK-2 cells express vimentin that is usually considered to be characteristic for 
mesenchymal cells. However, normal HK-2 cells makes perinuclear aggregation of vimentin 
intermediate filaments, while upon injury vimentin filaments spread through the whole 
cytoplasmic compartment making a fine network appearance (133). Thus, in order to follow 
vimentin expression during EMT changes in HK-2 cells, careful consideration should be done. 
Indeed, appearance of vimentin in cells is not a sign of EMT because normal cells also have this 
filament protein, but the pattern of its expression could suggest cell injury and the widespread 
appearance in the cytoplasm should be considered as mesenchymal characteristic. In our 
experiments, vimentin was found to be abundantly expressed in HK-2 cells towards TGF-β1 
stimulation. However, FGFR inhibitor restored the pattern of vimentin expression to perinuclear 
localization, as also observed in control. 
E-cadherin and N-cadherin 
Moreover, tubular epithelial cells in humans have several specificities with regard to expression 
of cadherins. It is widely accepted that switch from E-cadherin to N-cadherin culminates toward 
EMT. However, normal proximal tubular epithelial cells in human and rats already express N-
cadherin, instead of E-cadherin that makes tight-junctions in many epithelial structures including 
proximal tubuli in mice. According to our results, mRNA level of N-cadherin was up-regulated 
upon EMT program induction and was normalized by FGFR inhibitor application, whereas 
immunofluorescence did not show any difference with regard to expression patterns. Thus, N-
cadherin was almost identically visible on the cell membranes of HK-2 cells in all experimental 
groups. On the other hand, E-cadherin mRNA levels were repressed by TGF-β1 stimulation, 
while inhibition of NCAM/FGFR signaling in these cells normalized E-cadherin mRNA levels. 
These results could support the findings in the literature that upon EMT induction epithelial cells 
switch their cadherin phenotype by increased expression of N-cadherin and decreased E-cadherin 
levels. Moreover, it has been shown that loss of E-cadherin induces NCAM up-regulation (14). 
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However, here we present that NCAM up-regulation in response to TGF-β1 precedes E-cadherin 
down-regulation.  
SNAIL, SLUG and TWIST 
SNAIL superfamily (including SNAIL and SLUG) and TWIST transcription factors are 
fundamental in the induction of EMT. They regulate gene expression, stimulating those 
characteristic for mesenchymal cells and suppressing genes defined to be characteristic for 
epithelial cells. These transcription factors can be induced by several up-stream factors, 
including TGF-β1 (134, 135). However, transcriptional induction of SNAIL upon TGF-β1 
stimulation is direct consequence of SMAD2/3 phosphorylation which making a complex with 
SMAD4 translocate in the nuclear compartment stimulating SNAIL transcription. On the other 
hand, induction of TWIST transcription towards TGF-β1 is also regulated by STAT3 (134). 
Down-stream targets of TWIST and SNAIL family are numerous, but in the EMT context the 
most important is repression of E-cadherin. This repression is a direct consequence of SNAIL 
phosphorylation, whereby TWIST acts through the SLUG up-regulation which than in turns 
suppress E-cadherin (136). Altogether, it becomes apparent that SNAIL family of transcription 
factors are key point convergence during EMT that further induce changes in cells phenotype 
influencing their behavior. 
In our investigation, all aforementioned transcription factors were induced by TGF-β1 and 
afterwards significantly down-regulated by inhibition of NCAM induced FGFR signaling, as 
obtained by qRT-PCR. Moreover, applying double imunofluorescence we found vary prominent 
SNAIL and TWIST expression both in cytoplasm and nuclei of TECs undergoing EMT, as 
previously also detected for SNAIL protein upon TGF-β induced EMT of mammary epithelial 
cells (137). However, administration of PD173074 succeeded to almost completely prevent 
SNAIL expression, while TWIST appeared to less sensitive to the NCAM/FGFR inhibition. 
Thus, despite inhibition of FGFR signaling TWIST was still visible on the protein levels, but its 
subcellular localization was mainly detected within cytoplasm, indirectly implicating a 
functional inhibition of TWIST putative roles during EMT. 
Beside TGF-β1, SNAIL can be also induced in response to receptor tyrosine kinases (RTKs) 
signaling, activated by HGF, FGF, or EGF, acting through the RAS-MAPK or PI3K-Akt 
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pathways (135). It further expands our findings, suggesting a following putative axis of gene 
regulation: TGF-β1/NCAM/FGFR1/SNAIL, meaning that upon TGF-β stimulation SNAIL can 
be induced through the pSMAD2/3/4 manner and additionally by the induction of RTKs 
signaling (NCAM/FGFR1 signaling). The impotence of our findings can be supported with 
previous report where it has been shown that signaling via MAPK or PI3K are necessary and 
sufficient to regulate EMT in collaboration with TGF-β (138). 
α-SMA and FSP-1 
Both α-SMA and FSP-1 are considered as EMT markers and can be induced by TGF-β1 (23). 
Robust induction of both molecules was observed upon TGF-β1 simulation and was successfully 
suppressed by inhibition of NCAM/FGFR signaling in TECs. Furthermore, FSP-1 is found to be 
involved in the regulation of cell migration (127). Thus, beside ITGB1 modulation by 
PD173074, it might be that FSP-1 down-regulation is also one of the underling mechanisms of 
reduced cell capacity to migrate upon FGFR1 inhibition. Morphologically, α-SMA diffusely 
occupied cytoplasmic compartment upon induction of EMT program and could not be detected 
on the protein level in any cell treated with PD173074, implicating an important role of 
NCAM/FGFR signaling in the rearmament of cell cytoskeletal structure. Considering that α-
SMA is apparently expressed during fibroblast activation, as well as an important role of FGFR 
signaling in the same way (139), NCAM signaling through FGFR activation appears to be 
mechanisms driving acquisition of mesenchymal traits of tubular epithelial cells.     
Matrix-metalloproteinases (MMP2 and MMP9) 
MMPs, especially gelatinases MMP2 and MMP9 are up-regulated in response to tubular injury. 
Functionally, they promote degradation of basement membrane, thus providing an access of 
injured tubular cells to the interstitium, thereby facilitating cell migration (119, 140). Restoration 
of MMP2 an MMP9 mRNA levels after treatment with PD173074, could be also a background 
feature of reduced cell motility in this experimental group, compared to cells treated with TGF-





Integrins (ITGA5 and ITGB1) 
Inhibition of NCAM/FGFR signaling leads to significant modulation of integrins’ expression 
initially induced by TGF-β1. However, ITGA5 responded slowly to such signaling modulation, 
since during the first two days mRNA levels were still higher than in controls but the third day 
after treatment it also normalized mRNA, similar to ITGB1 response. Since these integrins are 
considered to be hallmarks of EMT, their down-regulation which was also followed by cell 
morphology changes (reversal of spindle shaped to epithelial) and reduced migration capacity 
could be accepted as signs of MET (mesenchymal to epithelial transformation) observed upon 
inhibition of NCAM/FGFR signaling. 
Furthermore, it has been previously shown that ITGB1 is involved in the regulation cell 
migration behavior. It is known that NCAM induce cell migration through the interaction with 
ITGB1 (112). Moreover, an induction of ITGB1-FAK/ILK signaling axis is found to be 
underling mechanism of enhanced cell migration undergoing EMT induced by TWIST 
transcription factor (141). Thus, it might be that reduced cell migration observed upon 
PD173074 treatment appeared due to down-regulation of ITGB1, previously up-regulated in 
response to TGF-β.  
SMADs 
The main down-stream effectors of TGF-β are SMAD proteins. Among them, R-SMADs are 
fundamental for the EMT program induction. Both SMAD2 and SMAD3 phosphorylitaion 
induce cascade of gene reprogramming. When aberrant induction of TGF-β appears, intracellular 
signaling cross-talk becomes affected changing the cell fate. Thus, during EMT program, 
pSMAD2 and pSMAD3 translocate into nuclear compartment modulating gene expressions. 
These effects are manly induced by stimulation of SNAIL transcription which then triggers a 
wide range of gene expression changes.   
SMAD phosphorylation appears upon TGF-β1 to its receptor on the cell surface. Here we 
detected by immunofluorescent staining the presence of pSMAD2/3 in cytoplasmic compartment 
24h after TGF-β1 stimulation and found them in the nuclei next two days. Suppression of 
NCAM/FGFR signaling by small ATP inhibitor (PD173074) does not influence SMAD 
phosphorylation, as we observed pSMAD2 and pSMAD3 in the cylosol one day after treatment. 
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However, even next experimental day (48h) and also 72h after NCAM/FGFR signaling 
inhibition in cells stimulated with TGF-β1, neither pSMAD2 nor SMAD3 could be observed in 
cells. This finding has to be further clarified, since it is not clear why inhibition of FGFR 
signaling results in disappearance of pSMAD2/3. It might be this inhibition promotes 
ubiquitination and degradation of activated SMADs, but underling mechanisms has to be 
resolved.       
Plasticity of EMT and opportunity for managements 
Although TGF signaling triggers robust EMT activation in epithelial cells, either during wound 
healing and tissue repair or during carcinogenesis, a reversal of the EMT phenotype could also 
appear at some time point, indicating natural termination of EMT and subsequent acquisition of 
epithelial traits again or effects of induced pharmacological inhibition, indicating a high degree 
of plasticity in the EMT process (136). 
TGF-β1, a major inducer of EMT program and fibrosis, has been previously shown that induces 
over-expression of FGFR family members and stimulates NCAM up-regulation (88, 105). Our 
previous research revealed increased NCAM expression in interstitial kidney compartment in the 
initial renal fibrosis with consecutive disappearance in later fibrosis stages in human kidneys 
(85). These observations encouraged us to further consider possible role of NCAM molecule in 
kidney fibrosis, especially during the initiation of such process. Despite controversial opinions 
with regard to existence of EMT driving fibrosis in vivo (110, 111), in vitro studies could be 
helpful in determination of molecular function and could provide more conclusive and confident 
data in order to clarify significance of previously observed phenomenon. Since we also detected 
that NCAM expressing renal interstitial cells in human kidneys occasionally express FGFR 
molecule (129), and considering their potential cross-talk with subsequent signaling stimulation 
(24-26, 99-101), we here explored for the first time significance and involvement of 
NCAM/FGFR interplay during EMT program in cultured TECs.  
NCAM and FGFR signaling alone have already been described during EMT program and it has 
been noticed that both molecules are fundamental for EMT in vitro (14, 25, 99, 100, 102). 
However, relevance of their interplay during EMT program in kidney has not been evaluated yet, 
although cross reactions of NCAM and FGFR are known to be significant in oncology researches 
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(101). It is well known that functional cooperation between these two molecules results in 
induction of FGFR signaling directly stimulated by NCAM molecule (14, 25, 26). However, 
FGFR signaling induced by NCAM stimulation differs from the pathway initiated by other 
ligands such as FGF. In the absence of FGF, activation of FGFR by NCAM specifically 
promotes characteristic FGF receptor cellular trafficking and recycling that results in sustained 
FGFR signaling (14, 27), leading to enhanced cell migration with invasive and aggressive 
biological behavior (99, 101, 142). 
Since we observed early induction of NCAM and FGFR1 upon exposure to TGF-β1, as proto-
typical mediator of intrarenal EMT program, even before EMT hallmarks became apparent, it 
was reasonable to consider an opportunity to modulate or even prevent EMT program by 
modulation of NCAM/FGFR signaling responses, especially considering that TGF- β1 plays an 
important role in development renal fibrosis in humans influencing excretory kidney function. 
The majority of morphological and molecular TGF-β1 induced changes of TECs were obviously 
suppressed by inhibition of NCAM induced FGFR signaling, afterwards confirmed as acting 
through SMAD dependant manner. Altogether, it becomes apparent that NCAM and FGFR1 are 
the earliest up-regulated molecules upon TGF- β1 stimulated EMT program whose mechanistic 
co-operation can be effectively suppressed by FGFR inhibitor (PD173074) administration.  An 
efficiency of PD73074 to modulate EMT events during carcinogenesis has been already 
investigated, as well as its therapeutical potential to reduce hearth fibrosis (143-147).     
Considering renal fibrosis as a common consequence of many kidney diseases, requirements for 
novel anti-fibrotic therapies are growing (92). For the first time, we here provide evidence for a 
direct mechanistic link between NCAM and FGFR signaling in initiation of EMT program 
TECs, and also explore clinical relevance of TGF-β1 downstream effectors detection in human 
kidney biopsies revealing their association with impaired renal excretory function and chronic 
kidney disease development. Since aberrant NCAM/FGFR signaling is equally present among 
various human renal diseases especially at the beginning of renal interstitial fibrosis (129), and 
TGF-β1 is considered as master inducer of fibrogenic response in the kidney, our current 
findings could have significant translational implications. Finally, modulation of such 
NCAM/FGFR signaling as established by PD173074 effectively blocks EMT program in 
cultured TECs, offering new insights into aberrant EMT program during renal fibrosis and new 
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therapeutical targets for such EMT program. Since therapeutic efficacy of PD173074 has been 
investigated and proven in various cancers but also non-cancerous diseases and already entered 
clinical testing, our findings expand our knowledge of a putative role of NCAM/FGFR in EMT 
program initiation and renal fibrosis and it is attractive to speculate that specific modulation of 
such NCAM/FGFR signaling could be equally effective in the treatment of renal disease 
associated with aberrant EMT program.  
The substance explored in this investigation (PD173074) belongs to receptor tyrosine kinases 
(RTKs) inhibitors (TKIs). Since RTKs signaling pathway a crucial in various pathological 
processes, including malignancies and fibrosis, numerous TKIs are widely studied and many of 
them are already in clinical use or are subjected to clinical trials (148, 149). However, among 
proposed therapies selective inhibitors are scarce, but rather involve inhibition of several RTKs. 
Thus, controversies about application of non-selective therapy still exist. Considering that in 
many pathological states an aberrant induction of several signaling pathways appear and can also 
involve signaling by several RTKs, therapy with non-selective TKIs could be more promising 
and with extended benefits. However, this opportunity could be retained only for management of 
malignancies and appears to be unsuitable for non-malignant conditions, such as fibrosis (150). 
Many TKIs are already explored in animal models of renal fibrosis, focusing mainly on the 
inhibition of platelet-derived growth factor receptor (PDGFR), epidermal growth factor receptor 
(EGFR) and vascular endothelial growth factor receptor (VEGFR). With regard to FGFR 
signaling in pathogenesis of renal diseases, it has been only proven that FGFR1 and its ligand 
FGF2 (basic FGF) are involved in the induction of renal fibrosis and contribution to renal 
damage in immune-mediated injury (149). Moreover, using fibroblast cell line, it has been shown 
that TGF-β1 induced fibroblast proliferation through the up-regulation of FGF2 synthesis, 
implicating a significant role of FGFR1 signaling (151). Thus, FGFR signaling is already known 
to be activated by TGF-β1 in fibroblasts. However, here we present an involvement of FGFR 
signaling in epithelial cells and induction of EMT program induced by non-FGF ligand 
(NCAM). This finding confirms again that FGFR acts down-stream of TGF- β1 and provides a 
novel mechanism of its induction, as shown – stimulated with aberrant NCAM expression 
rapidly induced upon TGF- β1 and in line with FGFR1 over-expression. Considering that low 
dose of PD73074 is found to be FGFR selective, mostly affected FGFR1 activity, it could 
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designate this substance to be a choice for management of early fibrosis, thus preventing a 
widespread fibrogenesis in kidney and terminal renal fibrosis with end-stage kidney disease 
(ESKD) occurrence.  
Kidney diseases are important problem worldwide. They are defined as impaired kidney 
structure or function, influencing global health of those individuals. Any kidney disease can 
occur abruptly and afterwards either resolve or become chronic. Chronic kidney disease (CKD) 
is a general term that considers heterogeneous disorders affecting renal function and kidney 
morphology with wide range of clinical presentation patterns. Clinical presentations could be 
related to cause of disease, its severity and the progression rate. Impairment of renal excretory 
function is considered as the most serious outcome of CKD. Earlier stages of kidney disease 
could be asymptomatic and are usually detected during routine comorbid evaluations. These 
stages could be reversible, while more severe presentation often have progressive disease course.    
Patients with pathohistologicaly revealed underlying kidney damage are considered to have 
CKD. Depending on the estimated glomerular filtration rate (eGFR) and albuminuria levels, 
patients are classified in four CKD prognostic/risk categories: low, moderate, high and vary high 
risk. According to KDIGO recommendations (3), all patients have to be carefully monitored and 
management of progression and CKD complications is still challenging. All people with CKD 
are risk to develop acute kidney injury, and all of them with disease progression could develop 
complications such as anemia, metabolic bone disease including laboratory abnormalities, 
acidosis, cardiovascular and cerebrovascular diseases. Targeted therapies could provide better 
balance between beneficial and adverse effects. Thus, defining the main signaling pathway and 
discovering the major inducer underling fibrogenesis with individual approach might not be cost-
effective option, but could be the most appropriate choice for patients and clinicians in the 








NCAM expressing cells do not only increase during fibrogenesis but also switch the isoforms. 
Compared to NCAM expressing in normal human kidneys, these cell under fibrotic 
microenvironment highly express NCAM-140 isoform. NCAM expression in renal interstitial 
compartment is disease independent, representing a trait of early fibrogenesis in the human 
kidney. These cells are highly heterogeneous, whereby sub-populations share some markers 
involved in fibrosis. Moreover, relative gene expression levels involved in fibrosis, assessed by 
qRT-PCR, were higher in advanced stages and NCAM followed that trend.  However, interstitial 
NCAM expression does not have long term impact on disease outcome and could not be used as 
predictor for the impairment of kidney function. Moreover, NCAM interstitial positivity is 
frequently found in patients with lower range proteinuria values. 
Since TGF-β is the main cytokine involved the fibrogenic response, here we underline the 
influence of this signaling pathway on morphology of renal tubulointerstitial compartment 
suggesting its signaling cascade is visible in chronic parenchymal damage (tubular atrophy and 
interstitial fibrosis), resulting in impaired renal excretory function and CDK development and 
progression. Beside SMAD2 influence on morphology of renal tubulointerstitial compartment 
and patients’ outcome, SNAIL expression in podocytes is associated with nephrotic range 
proteinuria. 
Collectively, the most important finding in our study reflects a robust induction of NCAM 
expression in incipient renal fibrosis and an important role of NCAM/FGFR interplay in the 
initiation step of fibrogenic response that could be effectively suppressed by inhibition of their 
cross-talk applying FGFR inhibitor (PD173074). Despite clear morphological and molecular 
evidence that PD173074 reduced TGF-β1 effects on proximal tubular epithelial cells in vitro 
through switch from EMT to MET like phenotype, great ambiguity still persists with regard to 
the precise background molecular mechanism and cross-talk between these two pathways, 
requiring profound clarification. Moreover, although it has been also previously observed that 
both NCAM and FGFR could be up-regulated in response to TGF-β1 stimulation, there is still 
gap in between since NCAM/FGFR up-stream inducers are not identified in response to TGF-β1 
signaling. TGF-β signaling can also induce non-SMAD dependant cellular response and it is 
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clear that the co-operation between SMAD and non-SMAD signaling pathways determines the 
final outcome of cellular response to TGF-β. Since both NCAM and FGFR1 are up-regulated 
rapidly after TGF-β1 stimulation and before morphological evidence of nuclear localization of 
pSMAD2/3, it might be that regulation of NCAM and FGFR1 gene expressions under the 
influence of TGF-β1 involves non-SMAD pathways. Nevertheless, since inhibition of 
NCAM/FGFR signaling pathway by administration of PD173074 results in suppression of 
nuclear translocation of SMAD2/3 and promotes their degradation in cytosol, it looks that TGF-
β1 reduced responses by PD173074 were highly SMAD dependant. 
Unequivocally, FGFR inhibitor could be a promising anti-fibrotic strategy for kidney diseases 
and has to be further explored at least on animal models, since investigations in the field of 
molecular background of renal interstitial fibrosis and signaling pathways driving initiation, 
maintenance and progression of such process could contribute to better understanding of the 
complex network involved in renal fibrosis and permit development of new potential strategies 
to treat renal fibrosis in humans. There is no cure for CKD that affects more than million lives 
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6. Autorstvo - deliti pod istim uslovima. Dozvoljavate umnožavanje, distribuciju i javno saopštavanje 
dela, i prerade, ako se navede ime autora na način određen od strane autora ili davaoca licence i ako se 
prerada distribuira pod istom ili sličnom licencom. Ova licenca dozvoljava komercijalnu upotrebu dela i 
prerada. Slična je softverskim licencama, odnosno licencama otvorenog koda. 
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